Two-site	O
interaction	O
of	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
with	O
activated	O
calcineurin	B-protein
.	O

Transcription	B-protein
factors	I-protein
belonging	O
to	O
the	O
nuclear	B-protein
factor	I-protein
of	I-protein
activated	I-protein
T	I-protein
cells	I-protein
(	I-protein
NFAT	I-protein
)	I-protein
family	I-protein
regulate	O
the	O
expression	O
of	O
cytokine	B-DNA
genes	I-DNA
and	O
other	O
inducible	O
genes	O
during	O
the	O
immune	O
response	O
.	O

The	O
functions	O
of	O
NFAT	B-protein
proteins	I-protein
are	O
directly	O
controlled	O
by	O
the	O
calcium-	B-protein
and	I-protein
calmodulin-	I-protein
dependent	I-protein
phosphatase	I-protein
calcineurin	B-protein
.	O

Here	O
we	O
show	O
that	O
the	O
binding	O
of	O
calcineurin	B-protein
to	O
NFAT	B-protein
is	O
substantially	O
increased	O
when	O
calcineurin	B-protein
is	O
activated	O
with	O
calmodulin	B-protein
and	O
calcium	O
.	O

FK506.FKBP12	O
drug-immunophilin	O
complexes	O
inhibited	O
the	O
interaction	O
of	O
NFAT	B-protein
with	O
activated	O
calcineurin	B-protein
much	O
more	O
effectively	O
than	O
they	O
inhibited	O
the	O
interaction	O
with	O
inactive	O
calcineurin	B-protein
,	O
suggesting	O
that	O
part	O
of	O
the	O
interaction	O
with	O
activated	O
calcineurin	B-protein
involved	O
the	O
enzyme	B-DNA
active	I-DNA
site	I-DNA
.	O

We	O
have	O
previously	O
shown	O
that	O
NFAT	B-protein
is	O
targeted	O
to	O
inactive	O
calcineurin	B-protein
at	O
a	O
region	O
distinct	O
from	O
the	O
calcineurin	B-DNA
active	I-DNA
site	I-DNA
(	O
Aramburu	O
,	O
J.	O
,	O
Garcia-Cozar	O
,	O
F.	O
J.	O
,	O
Raghavan	O
,	O
A.	O
,	O
Okamura	O
,	O
H.	O
,	O
Rao	O
,	O
A.	O
,	O
and	O
Hogan	O
,	O
P.	O
G.	O
(	O
1998	O
)	O
Mol.	O
Cell	O
1	O
,	O
627-637	O
)	O
;	O
this	O
region	O
is	O
also	O
involved	O
in	O
NFAT	B-protein
binding	O
to	O
activated	O
calcineurin	B-protein
,	O
since	O
binding	O
is	O
inhibited	O
by	O
an	O
NFAT	O
peptide	O
spanning	O
the	O
calcineurin	B-protein
docking	O
site	O
on	O
NFAT	B-protein
.	O

The	O
interacting	O
surfaces	O
are	O
located	O
on	O
the	O
catalytic	B-protein
domain	I-protein
of	O
the	O
calcineurin	B-protein
A	I-protein
chain	I-protein
and	O
on	O
an	O
86-amino	B-protein
acid	I-protein
fragment	I-protein
of	O
the	O
NFAT	B-protein
regulatory	I-protein
domain	I-protein
.	O

NFAT	B-protein
binding	O
to	O
the	O
calcineurin	B-protein
catalytic	I-protein
domain	I-protein
was	O
inhibited	O
by	O
the	O
calcineurin	B-protein
autoinhibitory	I-protein
domain	I-protein
and	O
the	O
RII	O
substrate	O
peptide	O
,	O
which	O
bind	O
in	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
,	O
as	O
well	O
as	O
by	O
the	O
NFAT	B-protein
docking	O
site	O
peptide	O
,	O
which	O
binds	O
to	O
a	O
region	O
of	O
calcineurin	B-protein
distinct	O
from	O
the	O
active	B-protein
site	I-protein
.	O

We	O
propose	O
that	O
,	O
in	O
resting	B-cell_type
cells	I-cell_type
,	O
NFAT	B-protein
is	O
targeted	O
to	O
a	O
region	O
of	O
the	O
calcineurin	B-protein
catalytic	I-protein
domain	I-protein
that	O
does	O
not	O
overlap	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
.	O

Upon	O
cell	O
activation	O
,	O
displacement	O
of	O
the	O
autoinhibitory	B-protein
domain	I-protein
by	O
calmodulin	B-protein
binding	O
allows	O
NFAT	B-protein
to	O
bind	O
additionally	O
to	O
the	O
calcineurin	B-protein
active	I-protein
site	I-protein
,	O
thus	O
positioning	O
NFAT	B-protein
for	O
immediate	O
dephosphorylation	O
at	O
functional	O
phosphoserine	O
residues	O
.	O

THE	NULL
JOURNAL	NULL
oF	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1998	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

273	NULL
,	NULL
No	NULL
.	NULL

37	NULL
,	NULL
Issue	NULL
of	NULL
September	NULL
11	NULL
,	NULL
pp	NULL
.	NULL

23877-23883	NULL
,	NULL
1998	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Two-site	NULL
Interaction	NULL
of	NULL
Nuclear	NULL
Factor	NULL
of	NULL
Activated	NULL
T	NULL
Cells	NULL
with	NULL
Activated	NULL
Calcineurin*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
April	NULL
28	NULL
,	NULL
1998	NULL
)	NULL
Francisco	NULL
J.	NULL
Garcia-Cozar	NULL
$	NULL
,	NULL
Heidi	NULL
Okamurat	NULL
,	NULL
Jose	NULL
F.	NULL
Aramburut	NULL
,	NULL
Karen	NULL
T.	NULL
Y.	NULL
Shaw	NULL
$	NULL
§	NULL
,	NULL
Laura	NULL
Pelletier	NULL
]	NULL
,	NULL
Richard	NULL
Showalter1	NULL
,	NULL
Ernest	NULL
Villafranca	NULL
,	NULL
and	NULL
Anjana	NULL
Rao	NULL
#	NULL
]	NULL
From	NULL
the	NULL
{	NULL
Department	NULL
of	NULL
Pathology	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
and	NULL
the	NULL
Center	NULL
for	NULL
Blood	NULL
Research	NULL
,	NULL
Boston	NULL
,	NULL
Massachusetts	NULL
02115	NULL
and	NULL
Agouron	NULL
Pharmaceuticals	NULL
Inc.	NULL
,	NULL
San	NULL
Diego	NULL
,	NULL
California	NULL
92121	NULL
Transcription	NULL
factors	NULL
belonging	NULL
to	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
family	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
cytokine	NULL
genes	NULL
and	NULL
other	NULL
inducible	NULL
genes	NULL
during	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

The	NULL
functions	NULL
of	NULL
NFAT	NULL
proteins	NULL
are	NULL
directly	NULL
controlled	NULL
by	NULL
the	NULL
calcium-	NULL
and	NULL
calmodulin-dependent	NULL
phosphatase	NULL
calcineurin	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
calcineurin	NULL
to	NULL
NFAT	NULL
is	NULL
substantially	NULL
increased	NULL
when	NULL
calcineurin	NULL
is	NULL
activated	NULL
with	NULL
calmodulin	NULL
and	NULL
calcium	NULL
.	NULL

FK506-FKBP12	NULL
drug-immunophilin	NULL
complexes	NULL
inhibited	NULL
the	NULL
interaction	NULL
of	NULL
NFAT	NULL
with	NULL
activated	NULL
calcineurin	NULL
much	NULL
more	NULL
effectively	NULL
than	NULL
they	NULL
inhibited	NULL
the	NULL
interaction	NULL
with	NULL
inactive	NULL
calcineurin	NULL
,	NULL
suggesting	NULL
that	NULL
part	NULL
of	NULL
the	NULL
interaction	NULL
with	NULL
activated	NULL
calcineurin	NULL
involved	NULL
the	NULL
enzyme	NULL
active	NULL
site	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
NFAT	NULL
is	NULL
targeted	NULL
to	NULL
inactive	NULL
calcineurin	NULL
at	NULL
a	NULL
region	NULL
distinct	NULL
from	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
(	NULL
Aram-buru	NULL
,	NULL
J.	NULL
,	NULL
Garcia-Cozar	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Raghavan	NULL
,	NULL
A.	NULL
,	NULL
Okamura	NULL
,	NULL
H.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
1	NULL
,	NULL
627-637	NULL
)	NULL
;	NULL
this	NULL
region	NULL
is	NULL
also	NULL
involved	NULL
in	NULL
NFAT	NULL
binding	NULL
to	NULL
activated	NULL
calcineurin	NULL
,	NULL
since	NULL
binding	NULL
is	NULL
inhibited	NULL
by	NULL
an	NULL
NFAT	NULL
peptide	NULL
spanning	NULL
the	NULL
calcineurin	NULL
docking	NULL
site	NULL
on	NULL
NFAT	NULL
.	NULL

The	NULL
interacting	NULL
surfaces	NULL
are	NULL
located	NULL
on	NULL
the	NULL
catalytic	NULL
domain	NULL
of	NULL
the	NULL
calcineurin	NULL
A	NULL
chain	NULL
and	NULL
on	NULL
an	NULL
86-amino	NULL
acid	NULL
fragment	NULL
of	NULL
the	NULL
NFAT	NULL
regulatory	NULL
domain	NULL
.	NULL

NFAT	NULL
binding	NULL
to	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
calcineurin	NULL
autoinhibitory	NULL
domain	NULL
and	NULL
the	NULL
RII	NULL
substrate	NULL
peptide	NULL
,	NULL
which	NULL
bind	NULL
in	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
the	NULL
NFAT	NULL
docking	NULL
site	NULL
peptide	NULL
,	NULL
which	NULL
binds	NULL
to	NULL
a	NULL
region	NULL
of	NULL
calcineurin	NULL
distinct	NULL
from	NULL
the	NULL
active	NULL
site	NULL
.	NULL

We	NULL
propose	NULL
that	NULL
,	NULL
in	NULL
resting	NULL
cells	NULL
,	NULL
NFAT	NULL
is	NULL
targeted	NULL
to	NULL
a	NULL
region	NULL
of	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
that	NULL
does	NULL
not	NULL
overlap	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
.	NULL

Upon	NULL
cell	NULL
activation	NULL
,	NULL
displacement	NULL
of	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
by	NULL
calmodulin	NULL
binding	NULL
allows	NULL
NFAT	NULL
to	NULL
bind	NULL
additionally	NULL
to	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
,	NULL
thus	NULL
positioning	NULL
NFAT	NULL
for	NULL
immediate	NULL
dephosphorylation	NULL
at	NULL
functional	NULL
phosphoserine	NULL
residues	NULL
.	NULL

*	NULL
This	NULL
work	NULL
was	NULL
supported	NULL
in	NULL
part	NULL
by	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Grant	NULL
Al	NULL
40127	NULL
(	NULL
to	NULL
A.	NULL
R.	NULL
)	NULL
,	NULL
a	NULL
Formaciéon	NULL
de	NULL
Personal	NULL
Investigador	NULL
postdoctoral	NULL
fellowship	NULL
award	NULL
from	NULL
the	NULL
Spanish	NULL
Ministry	NULL
of	NULL
Science	NULL
and	NULL
Education	NULL
(	NULL
to	NULL
F.	NULL
J.	NULL
G.-C.	NULL
)	NULL
,	NULL
a	NULL
Cancer	NULL
Research	NULL
Institute	NULL
fellowship	NULL
(	NULL
to	NULL
H	NULL
.	NULL

O	NULL
.	NULL
)	NULL

,	NULL
a	NULL
Medical	NULL
Research	NULL
Council	NULL
fellowship	NULL
(	NULL
to	NULL
K.	NULL
T.	NULL
Y.	NULL
S.	NULL
)	NULL
,	NULL
an	NULL
Arthritis	NULL
Foundation	NULL
postdoctoral	NULL
fellowship	NULL
(	NULL
to	NULL
J.	NULL
F	NULL
.	NULL

A	NULL
.	NULL
)	NULL

,	NULL
and	NULL
a	NULL
Leukemia	NULL
Society	NULL
of	NULL
America	NULL
scholar	NULL
award	NULL
(	NULL
to	NULL
A.	NULL
R	NULL
)	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

§	NULL
Present	NULL
address	NULL
:	NULL
National	NULL
Institute	NULL
of	NULL
Aging	NULL
,	NULL
National	NULL
Institutes	NULL
of	NULL
Health	NULL
Intramural	NULL
Research	NULL
Program	NULL
,	NULL
Gerontology	NULL
Research	NULL
Center	NULL
,	NULL
5600	NULL
Nathan	NULL
Shock	NULL
Drive	NULL
,	NULL
Baltimore	NULL
,	NULL
MD	NULL
21224	NULL
.	NULL

|	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Dept	NULL
.	NULL

of	NULL
Pathology	NULL
,	NULL
Harvard	NULL
Medical	NULL
School	NULL
,	NULL
The	NULL
Center	NULL
for	NULL
Blood	NULL
Research	NULL
,	NULL
200	NULL
Longwood	NULL
Ave.	NULL
,	NULL
Boston	NULL
,	NULL
MA	NULL
02115	NULL
.	NULL

Tel	NULL
.	NULL

:	NULL
617-278-8260/8261	NULL
;	NULL
Fax	NULL
:	NULL
617-278-3280	NULL
;	NULL
E-mail	NULL
:	NULL
arao	NULL
@	NULL
cbr.med.harvard.edu	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
Proteins	NULL
belonging	NULL
to	NULL
the	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
(	NULL
NFAT	NULL
)	NULL
family	NULL
are	NULL
a	NULL
family	NULL
of	NULL
transcription	NULL
factors	NULL
that	NULL
regulate	NULL
the	NULL
expression	NULL
of	NULL
many	NULL
inducible	NULL
genes	NULL
during	NULL
the	NULL
immune	NULL
response	NULL
(	NULL
1-5	NULL
)	NULL
(	NULL
reviewed	NULL
in	NULL
Rao	NULL
et	NULL
al	NULL
.	NULL

(	NULL
6	NULL
)	NULL
)	NULL
.	NULL

NFAT	NULL
proteins	NULL
are	NULL
expressed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
immune	NULL
system	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
endothelial	NULL
cells	NULL
,	NULL
certain	NULL
neuronal	NULL
cells	NULL
,	NULL
and	NULL
other	NULL
cells	NULL
outside	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
6-12	NULL
)	NULL
.	NULL

NFAT	NULL
proteins	NULL
contain	NULL
two	NULL
adjacent	NULL
~300-amino	NULL
acid	NULL
regions	NULL
that	NULL
are	NULL
conserved	NULL
within	NULL
the	NULL
NFAT	NULL
family	NULL
,	NULL
a	NULL
regulatory	NULL
domain	NULL
located	NULL
near	NULL
the	NULL
N	NULL
terminus	NULL
and	NULL
a	NULL
strongly	NULL
conserved	NULL
DNA	NULL
binding	NULL
domain	NULL
(	NULL
4-6	NULL
,	NULL
13-18	NULL
)	NULL
.	NULL

In	NULL
resting	NULL
cells	NULL
,	NULL
NFAT	NULL
proteins	NULL
are	NULL
phosphorylated	NULL
and	NULL
reside	NULL
in	NULL
the	NULL
cytoplasm	NULL
;	NULL
upon	NULL
stimulation	NULL
of	NULL
cells	NULL
with	NULL
calcium-mobiliz-ing	NULL
agents	NULL
,	NULL
they	NULL
become	NULL
dephosphorylated	NULL
and	NULL
translocate	NULL
rapidly	NULL
to	NULL
the	NULL
nucleus	NULL
(	NULL
6	NULL
,	NULL
7	NULL
,	NULL
13	NULL
,	NULL
15	NULL
,	NULL
16	NULL
,	NULL
19	NULL
,	NULL
20	NULL
)	NULL
.	NULL

In	NULL
the	NULL
nucleus	NULL
,	NULL
they	NULL
interact	NULL
cooperatively	NULL
with	NULL
Fos-Jun	NULL
proteins	NULL
and	NULL
possibly	NULL
other	NULL
transcription	NULL
factors	NULL
to	NULL
modulate	NULL
gene	NULL
transcription	NULL
(	NULL
6	NULL
,	NULL
21-24	NULL
)	NULL
.	NULL

The	NULL
activity	NULL
of	NULL
NFAT	NULL
transcription	NULL
factors	NULL
is	NULL
directly	NULL
regulated	NULL
by	NULL
calcineurin	NULL
,	NULL
a	NULL
calcium-	NULL
and	NULL
calmodulin-dependent	NULL
phosphatase	NULL
also	NULL
known	NULL
as	NULL
protein	NULL
phosphatase	NULL
2B	NULL
(	NULL
6	NULL
,	NULL
25	NULL
)	NULL
.	NULL

Calcineurin	NULL
controls	NULL
multiple	NULL
functions	NULL
of	NULL
NFAT	NULL
proteins	NULL
,	NULL
including	NULL
their	NULL
nuclear	NULL
import	NULL
,	NULL
their	NULL
DNA-binding	NULL
affinity	NULL
,	NULL
and	NULL
their	NULL
transactivation	NULL
(	NULL
reviewed	NULL
in	NULL
Rao	NULL
et	NULL
al	NULL
.	NULL

(	NULL
6	NULL
)	NULL
)	NULL
.	NULL

Both	NULL
the	NULL
phosphorylated	NULL
and	NULL
dephosphorylated	NULL
forms	NULL
of	NULL
NFAT1	NULL
bind	NULL
to	NULL
calcineurin	NULL
immobilized	NULL
on	NULL
calmodulin-Sepharose	NULL
beads	NULL
(	NULL
13	NULL
,	NULL
26	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
has	NULL
been	NULL
mapped	NULL
to	NULL
the	NULL
N-terminal	NULL
regulatory	NULL
domains	NULL
of	NULL
NFAT	NULL
proteins	NULL
using	NULL
recombinant	NULL
NFAT1	NULL
and	NULL
NFAT2	NULL
expressed	NULL
in	NULL
bacteria	NULL
(	NULL
15	NULL
,	NULL
27	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
recombinant	NULL
NFAT	NULL
and	NULL
NFAT4	NULL
expressed	NULL
in	NULL
mammalian	NULL
cells	NULL
(	NULL
13	NULL
,	NULL
16	NULL
,	NULL
17	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Calcineurin	NULL
is	NULL
a	NULL
heterodimer	NULL
of	NULL
a	NULL
catalytic	NULL
A	NULL
subunit	NULL
and	NULL
a	NULL
calcium-binding	NULL
regulatory	NULL
B	NULL
subunit	NULL
(	NULL
25	NULL
)	NULL
.	NULL

The	NULL
A	NULL
subunit	NULL
contains	NULL
the	NULL
catalytic	NULL
domain	NULL
at	NULL
its	NULL
N	NULL
terminus	NULL
,	NULL
followed	NULL
by	NULL
binding	NULL
regions	NULL
for	NULL
the	NULL
B	NULL
subunit	NULL
and	NULL
for	NULL
calmodulin	NULL
that	NULL
were	NULL
defined	NULL
by	NULL
deletion	NULL
and	NULL
mutational	NULL
analysis	NULL
(	NULL
28-31	NULL
)	NULL
.	NULL

An	NULL
autoinhibitory	NULL
domain	NULL
,	NULL
whose	NULL
removal	NULL
renders	NULL
calcineurin	NULL
constitutively	NULL
active	NULL
,	NULL
is	NULL
located	NULL
near	NULL
the	NULL
C	NULL
terminus	NULL
of	NULL
the	NULL
calcineurin	NULL
A	NULL
chain	NULL
(	NULL
29-31	NULL
)	NULL
.	NULL

Determination	NULL
of	NULL
the	NULL
calcineurin	NULL
structure	NULL
showed	NULL
that	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
forms	NULL
an	NULL
«	NULL
-helix	NULL
that	NULL
is	NULL
positioned	NULL
in	NULL
the	NULL
active	NULL
site	NULL
of	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
,	NULL
thus	NULL
preventing	NULL
the	NULL
access	NULL
of	NULL
substrates	NULL
to	NULL
the	NULL
active	NULL
site	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Both	NULL
in	NULL
human	NULL
and	NULL
in	NULL
bovine	NULL
calcineurin	NULL
,	NULL
the	NULL
B-chain	NULL
binding	NULL
region	NULL
is	NULL
also	NULL
a-helical	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
,	NULL
while	NULL
the	NULL
region	NULL
between	NULL
the	NULL
B-chain-binding	NULL
helix	NULL
and	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
is	NULL
disordered	NULL
in	NULL
the	NULL
crystal	NULL
structure	NULL
(	NULL
32	NULL
)	NULL
.	NULL

Calmodulin	NULL
binding	NULL
to	NULL
this	NULL
disordered	NULL
region	NULL
is	NULL
presumed	NULL
to	NULL
displace	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
from	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
,	NULL
thus	NULL
permitting	NULL
the	NULL
access	NULL
of	NULL
substrates	NULL
to	NULL
the	NULL
active	NULL
site	NULL
.	NULL

*	NULL
The	NULL
abbreviations	NULL
use	NULL
are	NULL
:	NULL
NFAT	NULL
,	NULL
nuclear	NULL
factor	NULL
of	NULL
activated	NULL
T	NULL
cells	NULL
,	NULL
CsA	NULL
,	NULL
cyclosporin	NULL
A	NULL
;	NULL
GST	NULL
,	NULL
glutathione	NULL
S-transferase	NULL
;	NULL
CyPA	NULL
,	NULL
cyclophilin	NULL
A	NULL
;	NULL
FKBP	NULL
,	NULL
FK506-binding	NULL
protein	NULL
;	NULL
CnCAT	NULL
,	NULL
catalytic	NULL
domain	NULL
of	NULL
cal	NULL
cineurin	NULL
;	NULL
LSF	NULL
,	NULL
late	NULL
SV40	NULL
transcription	NULL
factor	NULL
.	NULL

28877	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
23878	NULL
Interaction	NULL
of	NULL
Calcineurin	NULL
with	NULL
NFAT	NULL
GST-NFAT2	NULL
+	NULL
``	NULL
ro	NULL
incubate	NULL
measure	NULL
GST-LSF	NULL
~~	NULL
``	NULL
~~-wash	NULL
bound	NULL
cpm	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Calmodulin	NULL
enhances	NULL
the	NULL
A	NULL
B	NULL
binding	NULL
of	NULL
calcineurin	NULL
to	NULL
NFAT	NULL
.	NULL

'*I-	NULL
Calcineurin	NULL
(	NULL
Cr	NULL
)	NULL
(	NULL
4	NULL
nM	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
GST-NFAT2	NULL
or	NULL
GST-LSF	NULL
in	NULL
the	NULL
$	NULL
0	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
calcium	NULL
and/or	NULL
calmodulin	NULL
(	NULL
CaM	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

Reactions	NULL
lacking	NULL
calcium	NULL
contained	NULL
5	NULL
mM	NULL
EGTA	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
rapidly	NULL
washed	NULL
by	NULL
filtration	NULL
to	NULL
remove	NULL
unbound	NULL
calcineurin	NULL
,	NULL
and	NULL
bound	NULL
radioactivity	NULL
was	NULL
quantified	NULL
.	NULL

Reactions	NULL
lacking	NULL
calmodulin	NULL
contained	NULL
an	NULL
equivalent	NULL
concentration	NULL
(	NULL
500	NULL
nM	NULL
)	NULL
of	NULL
myo-globin	NULL
.	NULL

In	NULL
A	NULL
,	NULL
the	NULL
average	NULL
and	NULL
standard	NULL
deviation	NULL
of	NULL
a	NULL
representative	NULL
experiment	NULL
,	NULL
performed	NULL
in	NULL
triplicate	NULL
,	NULL
is	NULL
shown	NULL
.	NULL

Note	NULL
that	NULL
error	NULL
bars	NULL
for	NULL
some	NULL
triplicates	NULL
are	NULL
too	NULL
small	NULL
to	NULL
be	NULL
apparent	NULL
.	NULL

In	NULL
B	NULL
,	NULL
a	NULL
second	NULL
experiment	NULL
using	NULL
a	NULL
different	NULL
calcineurin	NULL
preparation	NULL
,	NULL
with	NULL
a	NULL
greater	NULL
calmodulin-dependent	NULL
increase	NULL
in	NULL
binding	NULL
,	NULL
is	NULL
shown	NULL
.	NULL

0	NULL
Ca++	NULL
CaM	NULL
a	NULL
&	NULL
I	NULL
fmol	NULL
I-Cn	NULL
bound	NULL
The	NULL
clinically	NULL
important	NULL
immunosuppressive	NULL
drugs	NULL
,	NULL
cyclosporin	NULL
A	NULL
(	NULL
CsA	NULL
)	NULL
and	NULL
FK506	NULL
,	NULL
have	NULL
long	NULL
been	NULL
known	NULL
to	NULL
inhibit	NULL
T	NULL
lymphocyte	NULL
activation	NULL
and	NULL
NFAT	NULL
activation	NULL
,	NULL
primarily	NULL
because	NULL
of	NULL
their	NULL
ability	NULL
to	NULL
inhibit	NULL
the	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
toward	NULL
phosphoprotein	NULL
substrates	NULL
(	NULL
reviewed	NULL
in	NULL
Refs	NULL
.	NULL

34-37	NULL
)	NULL
.	NULL

CsA	NULL
and	NULL
FK506	NULL
do	NULL
not	NULL
inhibit	NULL
calcineurin	NULL
activity	NULL
directly	NULL
,	NULL
but	NULL
form	NULL
inhibitory	NULL
complexes	NULL
with	NULL
intracellular	NULL
receptors	NULL
,	NULL
known	NULL
as	NULL
immunophilins	NULL
,	NULL
that	NULL
are	NULL
present	NULL
at	NULL
high	NULL
abundance	NULL
in	NULL
all	NULL
cells	NULL
;	NULL
the	NULL
immunophilin	NULL
receptors	NULL
for	NULL
CsA	NULL
are	NULL
known	NULL
as	NULL
cyclo-philins	NULL
(	NULL
CyPs	NULL
)	NULL
,	NULL
while	NULL
those	NULL
for	NULL
FK506	NULL
are	NULL
known	NULL
as	NULL
FK-binding	NULL
proteins	NULL
or	NULL
FKBPs	NULL
.	NULL

The	NULL
structures	NULL
of	NULL
human	NULL
and	NULL
bovine	NULL
calcineurin	NULL
,	NULL
in	NULL
complex	NULL
with	NULL
FK506-FKBP12	NULL
,	NULL
have	NULL
been	NULL
solved	NULL
:	NULL
the	NULL
drug-immunophilin	NULL
complex	NULL
binds	NULL
to	NULL
the	NULL
calcineurin	NULL
B-binding	NULL
a-helix	NULL
of	NULL
the	NULL
calcineurin	NULL
A	NULL
chain	NULL
and	NULL
inhibits	NULL
calcineurin	NULL
by	NULL
an	NULL
indirect	NULL
mechanism	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
.	NULL

Here	NULL
we	NULL
show	NULL
that	NULL
NFAT	NULL
proteins	NULL
interact	NULL
more	NULL
strongly	NULL
with	NULL
calmodulin-activated	NULL
than	NULL
inactive	NULL
calcineurin	NULL
.	NULL

Two	NULL
regions	NULL
of	NULL
calcineurin	NULL
are	NULL
implicated	NULL
in	NULL
the	NULL
interaction	NULL
,	NULL
both	NULL
of	NULL
which	NULL
are	NULL
located	NULL
on	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
.	NULL

One	NULL
of	NULL
these	NULL
is	NULL
a	NULL
targeting	NULL
region	NULL
complementary	NULL
to	NULL
a	NULL
region	NULL
we	NULL
have	NULL
recently	NULL
defined	NULL
as	NULL
the	NULL
docking	NULL
site	NULL
for	NULL
calcineurin	NULL
on	NULL
NFAT	NULL
(	NULL
27	NULL
)	NULL
,	NULL
while	NULL
the	NULL
second	NULL
is	NULL
a	NULL
region	NULL
overlapping	NULL
the	NULL
active	NULL
site	NULL
that	NULL
is	NULL
preferentially	NULL
exposed	NULL
in	NULL
activated	NULL
calmodulin-bound	NULL
calcineurin	NULL
.	NULL

Based	NULL
on	NULL
our	NULL
data	NULL
,	NULL
we	NULL
suggest	NULL
that	NULL
NFAT	NULL
proteins	NULL
are	NULL
targeted	NULL
to	NULL
calcineurin	NULL
in	NULL
resting	NULL
cells	NULL
,	NULL
and	NULL
that	NULL
they	NULL
make	NULL
an	NULL
additional	NULL
interaction	NULL
with	NULL
the	NULL
active	NULL
site	NULL
of	NULL
calcineurin	NULL
in	NULL
activated	NULL
cells	NULL
.	NULL

Our	NULL
results	NULL
have	NULL
implications	NULL
for	NULL
the	NULL
regulation	NULL
of	NULL
NFAT	NULL
by	NULL
calcineurin	NULL
in	NULL
resting	NULL
and	NULL
activated	NULL
cells	NULL
,	NULL
and	NULL
for	NULL
the	NULL
development	NULL
of	NULL
new	NULL
types	NULL
of	NULL
immunosuppressive	NULL
drugs	NULL
.	NULL

EXPERIMENTAL	NULL
PROCEDURES	NULL
Reagents-The	NULL
glutathione	NULL
S-transferase	NULL
(	NULL
GST	NULL
)	NULL
fusion	NULL
proteins	NULL
GST-LSF	NULL
,	NULL
GST-human	NULL
(	NULL
h	NULL
)	NULL
NFAT1	NULL
(	NULL
1-415	NULL
)	NULL
,	NULL
GST-hNFAT2	NULL
(	NULL
1-418	NULL
)	NULL
,	NULL
and	NULL
GST-hNFAT4	NULL
(	NULL
11-419	NULL
)	NULL
(	NULL
abbreviated	NULL
GST-NFAT1	NULL
,	NULL
GST-NFAT2	NULL
,	NULL
and	NULL
so	NULL
forth	NULL
)	NULL
have	NULL
been	NULL
described	NULL
(	NULL
27	NULL
,	NULL
38	NULL
)	NULL
.	NULL

The	NULL
hexahistidine-tagged	NULL
NFAT1	NULL
(	NULL
1-415	NULL
)	NULL
was	NULL
generated	NULL
by	NULL
subcloning	NULL
the	NULL
coding	NULL
region	NULL
for	NULL
the	NULL
415	NULL
N-terminal	NULL
amino	NULL
acids	NULL
of	NULL
NFAT1	NULL
into	NULL
the	NULL
pQE32	NULL
vector	NULL
(	NULL
Qiagen	NULL
)	NULL
.	NULL

Hexahistidine-tagged	NULL
NFAT1	NULL
truncation	NULL
mutants	NULL
were	NULL
generated	NULL
by	NULL
a	NULL
polymerase	NULL
chain	NULL
reaction	NULL
and	NULL
subcloned	NULL
into	NULL
pQE	NULL
vectors	NULL
(	NULL
Qiagen	NULL
)	NULL
.	NULL

Recombinant	NULL
bacterially	NULL
expressed	NULL
human	NULL
calcineurin	NULL
and	NULL
human	NULL
FKBP12	NULL
were	NULL
prepared	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
82	NULL
)	NULL
.	NULL

The	NULL
recombinant	NULL
catalytic	NULL
domain	NULL
of	NULL
human	NULL
calcineurin	NULL
(	NULL
CnCAT	NULL
)	NULL
,	NULL
incorporating	NULL
a	NULL
hexa-histidine	NULL
tag	NULL
at	NULL
the	NULL
C	NULL
terminus	NULL
,	NULL
was	NULL
made	NULL
by	NULL
expressing	NULL
amino	NULL
acids	NULL
1-847	NULL
in	NULL
bacteria	NULL
.	NULL

The	NULL
recombinant	NULL
bacterially	NULL
expressed	NULL
His	NULL
'	NULL
``	NULL
``	NULL
-	NULL
>	NULL
Ala	NULL
Fo	NULL
-	NULL
-+	NULL
4+	NULL
-	NULL
«	NULL
o-	NULL
-p	NULL
fo	NULL
NFAT2	NULL
LSF	NULL
NFAT2	NULL
)	NULL
LSF	NULL
150	NULL
100	NULL
50	NULL
o	NULL
LL	NULL
moze	NULL
+o	NULL
+	NULL
++	NULL
-	NULL
++	NULL
-o+	NULL
-	NULL
+	NULL
mutant	NULL
of	NULL
human	NULL
calcineurin	NULL
A	NULL
was	NULL
coexpressed	NULL
with	NULL
calcineurin	NULL
B	NULL
in	NULL
the	NULL
pET-15b	NULL
vector	NULL
,	NULL
and	NULL
was	NULL
a	NULL
kind	NULL
gift	NULL
of	NULL
Dr.	NULL
Jun	NULL
Liu	NULL
(	NULL
Massachusetts	NULL
Institute	NULL
of	NULL
Technology	NULL
)	NULL
(	NULL
89	NULL
)	NULL
.	NULL

Cyclophilin	NULL
A	NULL
(	NULL
CyPA	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Dr.	NULL
Christopher	NULL
Walsh	NULL
(	NULL
Harvard	NULL
Medical	NULL
School	NULL
)	NULL
.	NULL

Bovine	NULL
calcineurin	NULL
,	NULL
calmodulin	NULL
,	NULL
and	NULL
myoglobin	NULL
were	NULL
obtained	NULL
from	NULL
Sigma	NULL
.	NULL

The	NULL
RII	NULL
peptide	NULL
(	NULL
DLDVPIPGRFDRRVSVAAE	NULL
)	NULL
(	NULL
40	NULL
)	NULL
,	NULL
the	NULL
calcineurin	NULL
autoinhibitory	NULL
peptide	NULL
(	NULL
YITSFEEAKGLDRINERMPPRRDAMPSD	NULL
)	NULL
(	NULL
81	NULL
)	NULL
,	NULL
the	NULL
control	NULL
ovalbumin	NULL
peptide	NULL
(	NULL
41	NULL
)	NULL
,	NULL
and	NULL
the	NULL
SPRIEIT-25	NULL
(	NULL
KPAGASGP-SPRIEITPSHELMQAGGY	NULL
)	NULL
,	NULL
SPRIEIT-13	NULL
(	NULL
SGPSPRIEITPSH	NULL
)	NULL
,	NULL
and	NULL
SPAIAIA-25	NULL
(	NULL
KPAGASGPSPAIAIAPSHELMQAGGY	NULL
)	NULL
peptides	NULL
from	NULL
murine	NULL
NFAT1	NULL
(	NULL
27	NULL
)	NULL
were	NULL
synthesized	NULL
at	NULL
the	NULL
Tufts-New	NULL
England	NULL
Medical	NULL
Center	NULL
Peptide	NULL
Synthesis	NULL
Facility	NULL
.	NULL

For	NULL
some	NULL
experiments	NULL
the	NULL
RII	NULL
peptide	NULL
was	NULL
purchased	NULL
from	NULL
Bachem	NULL
Fine	NULL
Chemicals	NULL
,	NULL
Switzerland	NULL
.	NULL

The	NULL
polyclonal	NULL
rabbit	NULL
antiserum	NULL
directed	NULL
against	NULL
the	NULL
autoinhibitory	NULL
peptide	NULL
has	NULL
been	NULL
described	NULL
(	NULL
13	NULL
)	NULL
.	NULL

Protease	NULL
and	NULL
phosphatase	NULL
inhibitors	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
and	NULL
Calbiochem	NULL
.	NULL

lodination	NULL
of	NULL
Calcineurin-Calcineurin	NULL
or	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
(	NULL
CnCat	NULL
)	NULL
(	NULL
~100	NULL
ug	NULL
)	NULL
was	NULL
iodinated	NULL
with	NULL
1	NULL
mCi	NULL
carrier-free	NULL
Na	NULL
``	NULL
``	NULL
I	NULL
(	NULL
NEN	NULL
Life	NULL
Science	NULL
Products	NULL
)	NULL
using	NULL
IODO-BEADs	NULL
(	NULL
Pierce	NULL
)	NULL
,	NULL
then	NULL
separated	NULL
from	NULL
free	NULL
Na	NULL
``	NULL
``	NULL
I	NULL
on	NULL
a	NULL
Sephadex	NULL
G-25	NULL
spin	NULL
column	NULL
Biospin	NULL
6	NULL
(	NULL
Bio-Rad	NULL
)	NULL
and	NULL
stored	NULL
in	NULL
aliquots	NULL
at	NULL
-80	NULL
°C	NULL
.	NULL

Specific	NULL
activities	NULL
ranged	NULL
from	NULL
150	NULL
to	NULL
600	NULL
cpm/fmol	NULL
.	NULL

Identical	NULL
results	NULL
were	NULL
obtained	NULL
whether	NULL
recombinant	NULL
human	NULL
calcineurin	NULL
or	NULL
bovine	NULL
calcineurin	NULL
(	NULL
Sigma	NULL
)	NULL
were	NULL
used	NULL
in	NULL
the	NULL
binding	NULL
assay	NULL
.	NULL

Binding	NULL
Assays-In	NULL
some	NULL
experiments	NULL
,	NULL
calcineurin	NULL
binding	NULL
to	NULL
GST	NULL
proteins	NULL
was	NULL
assessed	NULL
by	NULL
Western	NULL
blotting	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
18	NULL
,	NULL
15	NULL
)	NULL
.	NULL

For	NULL
'**I-calcineurin	NULL
binding	NULL
to	NULL
GST	NULL
fusion	NULL
proteins	NULL
,	NULL
equivalent	NULL
amounts	NULL
of	NULL
GST-NFAT	NULL
or	NULL
GST-LSF	NULL
fusion	NULL
proteins	NULL
were	NULL
immobilized	NULL
on	NULL
gluthathione-Sepharose	NULL
beads	NULL
by	NULL
incubation	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
binding	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris	NULL
phosphate	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mM	NULL
MgCl	NULL
,	NULL
,	NULL
5	NULL
mM	NULL
2-mercaptoethanol	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
,	NULL
supplemented	NULL
with	NULL
1	NULL
mM	NULL
sodium	NULL
orthovanadate	NULL
,	NULL
20	NULL
uM	NULL
leupeptin	NULL
,	NULL
10	NULL
ug/ml	NULL
aprotinin	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
phenylmethylsulfonyl	NULL
fluoride	NULL
)	NULL
.	NULL

Beads	NULL
were	NULL
washed	NULL
,	NULL
resuspended	NULL
in	NULL
binding	NULL
buffer	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
'*	NULL
%	NULL
I-calcineurin	NULL
for	NULL
30	NULL
min	NULL
at	NULL
4	NULL
°C	NULL
.	NULL

Binding	NULL
of	NULL
calcineurin	NULL
to	NULL
hexahistidine-tagged	NULL
NFAT	NULL
proteins	NULL
was	NULL
assessed	NULL
after	NULL
binding	NULL
them	NULL
to	NULL
nickel-nitrilotriacetic	NULL
acid	NULL
beads	NULL
(	NULL
Qia-gen	NULL
)	NULL
;	NULL
in	NULL
these	NULL
experiments	NULL
30	NULL
mM	NULL
imidazole	NULL
was	NULL
added	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
and	NULL
to	NULL
the	NULL
washes	NULL
to	NULL
prevent	NULL
nonspecific	NULL
binding	NULL
of	NULL
calcineurin	NULL
to	NULL
the	NULL
nickel	NULL
beads	NULL
.	NULL

Background	NULL
binding	NULL
of	NULL
calcineurin	NULL
to	NULL
the	NULL
nickel	NULL
beads	NULL
is	NULL
shown	NULL
in	NULL
all	NULL
such	NULL
experiments	NULL
.	NULL

Final	NULL
concentrations	NULL
of	NULL
200	NULL
uM	NULL
CaCl	NULL
,	NULL
,	NULL
5	NULL
mM	NULL
EGTA	NULL
,	NULL
and	NULL
500	NULL
nM	NULL
calmodulin	NULL
were	NULL
used	NULL
unless	NULL
otherwise	NULL
noted	NULL
.	NULL

Where	NULL
indicated	NULL
,	NULL
CsA-CyPA	NULL
and	NULL
FK506FKBP12	NULL
complexes	NULL
,	NULL
formed	NULL
by	NULL
incubation	NULL
of	NULL
equimolar	NULL
concentrations	NULL
(	NULL
40-400	NULL
pM	NULL
)	NULL
of	NULL
the	NULL
drugs	NULL
with	NULL
the	NULL
immunophilins	NULL
for	NULL
1	NULL
h	NULL
on	NULL
ice	NULL
,	NULL
were	NULL
added	NULL
at	NULL
the	NULL
indicated	NULL
final	NULL
concentrations	NULL
to	NULL
the	NULL
binding	NULL
reaction	NULL
.	NULL

The	NULL
RII	NULL
,	NULL
autoinhibi-tory	NULL
,	NULL
and	NULL
control	NULL
peptides	NULL
were	NULL
used	NULL
at	NULL
final	NULL
concentrations	NULL
of	NULL
200	NULL
uM	NULL
.	NULL

SPRIEIT	NULL
and	NULL
SPAIAIA	NULL
peptides	NULL
were	NULL
used	NULL
at	NULL
the	NULL
indicated	NULL
final	NULL
con	NULL
centrations	NULL
.	NULL

After	NULL
incubation	NULL
,	NULL
individual	NULL
binding	NULL
reactions	NULL
were	NULL
filtered	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Interaction	NULL
of	NULL
Calcineurin	NULL
with	NULL
NFAT	NULL
8	NULL
Ca	NULL
CO	NULL
EGTA	NULL
H	NULL
Ca+CaM	NULL
23879	NULL
B	NULL
NFAT1	NULL
truncation	NULL
CN	NULL
mutant	NULL
binding	NULL
+++	NULL
140	NULL
>	NULL
07	NULL
Rs	NULL
:	NULL
+++	NULL
0	NULL
25	NULL
50	NULL
75	NULL
100	NULL
125	NULL
&	NULL
A	NULL
fmol	NULL
~I-Calcineurin	NULL
bound	NULL
125	NULL
150	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
short	NULL
fragment	NULL
of	NULL
NFAT	NULL
that	NULL
binds	NULL
to	NULL
calcineurin	NULL
.	NULL

A	NULL
,	NULL
***I-Calcineurin	NULL
(	NULL
10	NULL
nM	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
the	NULL
indicated	NULL
hexahistidine-tagged	NULL
truncated	NULL
derivatives	NULL
of	NULL
murine	NULL
NFAT1	NULL
(	NULL
1	NULL
ug	NULL
,	NULL
immobilized	NULL
on	NULL
nickel	NULL
beads	NULL
)	NULL
in	NULL
buffer	NULL
containing	NULL
30	NULL
mM	NULL
imidazole	NULL
and	NULL
EGTA	NULL
,	NULL
Ca	NULL
``	NULL
*	NULL
,	NULL
or	NULL
Ca**	NULL
and	NULL
calmodulin	NULL
(	NULL
CaM	NULL
)	NULL
as	NULL
indicated	NULL
.	NULL

The	NULL
level	NULL
of	NULL
binding	NULL
to	NULL
the	NULL
nickel	NULL
beads	NULL
alone	NULL
under	NULL
the	NULL
same	NULL
conditions	NULL
is	NULL
indicated	NULL
.	NULL

One	NULL
of	NULL
three	NULL
representative	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

B	NULL
,	NULL
schematic	NULL
summary	NULL
of	NULL
the	NULL
results	NULL
.	NULL

The	NULL
NFAT1	NULL
(	NULL
Q7-183	NULL
)	NULL
fragment	NULL
binds	NULL
calcineurin	NULL
as	NULL
well	NULL
as	NULL
NFAT1	NULL
(	NULL
1-415	NULL
)	NULL
.	NULL

through	NULL
a	NULL
5-um	NULL
hydrophilic	NULL
polyvinylidene	NULL
difluoride	NULL
filter	NULL
(	NULL
Millipore	NULL
)	NULL
using	NULL
a	NULL
vacuum	NULL
manifold	NULL
(	NULL
Millipore	NULL
)	NULL
to	NULL
separate	NULL
bound	NULL
and	NULL
unbound	NULL
*I-calcineurin	NULL
.	NULL

Filters	NULL
were	NULL
washed	NULL
rapidly	NULL
under	NULL
continuous	NULL
suction	NULL
with	NULL
24	NULL
ml	NULL
of	NULL
50	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.0	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
5	NULL
mm	NULL
MgCl	NULL
,	NULL
,	NULL
200	NULL
um	NULL
CaCl	NULL
,	NULL
,	NULL
10	NULL
%	NULL
glycerol	NULL
,	NULL
1	NULL
%	NULL
Triton	NULL
X-100	NULL
.	NULL

Washed	NULL
filters	NULL
were	NULL
transferred	NULL
to	NULL
tubes	NULL
and	NULL
**I-calcineurin	NULL
retained	NULL
by	NULL
the	NULL
immobilized	NULL
GST	NULL
or	NULL
hexahistidine-tagged	NULL
proteins	NULL
was	NULL
quantified	NULL
in	NULL
a	NULL
Hewlett	NULL
Packard	NULL
Gammacounter	NULL
.	NULL

RESULTS	NULL
AND	NULL
DISCUSSION	NULL
Activated	NULL
Calcineurin	NULL
Binds	NULL
More	NULL
Strongly	NULL
than	NULL
Does	NULL
Inactive	NULL
Calcineurin	NULL
to	NULL
NFAT-We	NULL
measured	NULL
the	NULL
binding	NULL
of	NULL
**°I-calcineurin	NULL
to	NULL
GST	NULL
fusion	NULL
proteins	NULL
containing	NULL
the	NULL
first	NULL
415	NULL
and	NULL
418	NULL
amino	NULL
acids	NULL
of	NULL
NFAT1	NULL
and	NULL
NFAT2	NULL
,	NULL
respectively	NULL
.	NULL

We	NULL
have	NULL
previously	NULL
shown	NULL
that	NULL
these	NULL
N-terminal	NULL
regions	NULL
of	NULL
NFAT	NULL
proteins	NULL
are	NULL
sufficient	NULL
for	NULL
calcineurin	NULL
binding	NULL
(	NULL
13	NULL
,	NULL
15	NULL
,	NULL
27	NULL
)	NULL
.	NULL

'*°I-Calcineurin	NULL
was	NULL
incubated	NULL
with	NULL
GST-NFAT1	NULL
or	NULL
GST-NFAT2	NULL
immobilized	NULL
on	NULL
glutathione	NULL
beads	NULL
,	NULL
and	NULL
radioactivity	NULL
bound	NULL
to	NULL
the	NULL
beads	NULL
was	NULL
rapidly	NULL
separated	NULL
by	NULL
filtration	NULL
.	NULL

Preliminary	NULL
experiments	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
indicated	NULL
that	NULL
peak	NULL
levels	NULL
of	NULL
**	NULL
``	NULL
T-cal-cineurin	NULL
binding	NULL
were	NULL
attained	NULL
by	NULL
30	NULL
min	NULL
,	NULL
and	NULL
that	NULL
binding	NULL
was	NULL
linear	NULL
with	NULL
the	NULL
amount	NULL
of	NULL
GST-NFAT	NULL
protein	NULL
used	NULL
.	NULL

Using	NULL
this	NULL
assay	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
**	NULL
``	NULL
T-cal-cineurin	NULL
to	NULL
NFAT1	NULL
and	NULL
NFAT2	NULL
was	NULL
markedly	NULL
dependent	NULL
on	NULL
the	NULL
presence	NULL
of	NULL
calcium	NULL
and	NULL
calmodulin	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
.	NULL

In	NULL
the	NULL
absence	NULL
of	NULL
calcium	NULL
(	NULL
i.e	NULL
.	NULL

in	NULL
buffer	NULL
containing	NULL
5	NULL
mm	NULL
EGTA	NULL
)	NULL
,	NULL
a	NULL
low	NULL
but	NULL
significant	NULL
level	NULL
of	NULL
binding	NULL
was	NULL
observed	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
open	NULL
bars	NULL
)	NULL
.	NULL

Note	NULL
that	NULL
this	NULL
low	NULL
level	NULL
of	NULL
binding	NULL
had	NULL
not	NULL
previously	NULL
been	NULL
detected	NULL
by	NULL
Western	NULL
blotting	NULL
(	NULL
13	NULL
,	NULL
15	NULL
)	NULL
,	NULL
confirming	NULL
that	NULL
the	NULL
binding	NULL
assay	NULL
using	NULL
iodinated	NULL
calcineurin	NULL
was	NULL
significantly	NULL
more	NULL
sensitive	NULL
.	NULL

In	NULL
the	NULL
presence	NULL
of	NULL
100	NULL
uM	NULL
calcium	NULL
,	NULL
there	NULL
was	NULL
a	NULL
substantial	NULL
increase	NULL
in	NULL
calcineurin	NULL
binding	NULL
to	NULL
NFAT1l	NULL
(	NULL
not	NULL
shown	NULL
)	NULL
and	NULL
NFAT2	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
gray	NULL
bars	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
our	NULL
earlier	NULL
results	NULL
using	NULL
Western	NULL
blot	NULL
analysis	NULL
(	NULL
13	NULL
,	NULL
15	NULL
)	NULL
.	NULL

When	NULL
calmodulin	NULL
was	NULL
included	NULL
in	NULL
the	NULL
binding	NULL
reaction	NULL
,	NULL
the	NULL
level	NULL
of	NULL
binding	NULL
was	NULL
again	NULL
reproducibly	NULL
increased	NULL
,	NULL
by	NULL
a	NULL
further	NULL
2-5-fold	NULL
depending	NULL
on	NULL
the	NULL
batch	NULL
of	NULL
iodinated	NULL
calcineurin	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
A	NULL
and	NULL
B	NULL
,	NULL
hatched	NULL
bars	NULL
)	NULL
.	NULL

As	NULL
expected	NULL
from	NULL
the	NULL
known	NULL
calcium	NULL
requirement	NULL
for	NULL
calmodulin	NULL
to	NULL
bind	NULL
and	NULL
activate	NULL
calcineurin	NULL
,	NULL
calmodulin	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
NFAT-calcineurin	NULL
association	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
calcium	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
black	NULL
bars	NULL
)	NULL
.	NULL

Neither	NULL
calcium	NULL
nor	NULL
calmodulin	NULL
had	NULL
any	NULL
effect	NULL
on	NULL
the	NULL
background	NULL
binding	NULL
of	NULL
calcineurin	NULL
to	NULL
the	NULL
unrelated	NULL
DNA-binding	NULL
protein	NULL
LSF	NULL
(	NULL
Fig	NULL
.	NULL

14	NULL
,	NULL
right	NULL
)	NULL
,	NULL
emphasizing	NULL
the	NULL
specificity	NULL
of	NULL
the	NULL
NFAT-calcineurin	NULL
association	NULL
.	NULL

Identification	NULL
of	NULL
a	NULL
Short	NULL
Fragment	NULL
of	NULL
NFAT1	NULL
That	NULL
Binds	NULL
to	NULL
Calcineurin-To	NULL
determine	NULL
the	NULL
region	NULL
of	NULL
NFAT1	NULL
involved	NULL
in	NULL
binding	NULL
calcineurin	NULL
,	NULL
we	NULL
tested	NULL
a	NULL
series	NULL
of	NULL
systematic	NULL
trunca-tions	NULL
of	NULL
the	NULL
NFAT1	NULL
regulatory	NULL
domain	NULL
,	NULL
expressed	NULL
as	NULL
hexahistidine-tagged	NULL
proteins	NULL
in	NULL
bacteria	NULL
.	NULL

These	NULL
experiments	NULL
identified	NULL
an	NULL
86-amino	NULL
acid	NULL
fragment	NULL
,	NULL
NFAT1	NULL
(	NULL
97-183	NULL
)	NULL
,	NULL
which	NULL
bound	NULL
calcineurin	NULL
as	NULL
effectively	NULL
as	NULL
the	NULL
original	NULL
NFAT1	NULL
(	NULL
1-415	NULL
)	NULL
recombinant	NULL
protein	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

A	NULL
shorter	NULL
fragment	NULL
,	NULL
NFATI1	NULL
(	NULL
Q7-144	NULL
)	NULL
,	NULL
was	NULL
also	NULL
able	NULL
to	NULL
bind	NULL
calcineurin	NULL
in	NULL
a	NULL
calcium-	NULL
and	NULL
calmodulin-dependent	NULL
fashion	NULL
,	NULL
but	NULL
binding	NULL
was	NULL
decreased	NULL
by	NULL
comparison	NULL
with	NULL
NFAT1	NULL
(	NULL
I-415	NULL
)	NULL
or	NULL
NFAT1	NULL
(	NULL
97-183	NULL
)	NULL
.	NULL

These	NULL
results	NULL
indicate	NULL
that	NULL
the	NULL
86-amino	NULL
acid	NULL
fragment	NULL
,	NULL
NFAT	NULL
(	NULL
97-183	NULL
)	NULL
,	NULL
contains	NULL
the	NULL
region	NULL
of	NULL
NFAT	NULL
involved	NULL
in	NULL
calcineurin	NULL
interaction	NULL
.	NULL

This	NULL
fragment	NULL
contains	NULL
the	NULL
sequence	NULL
``	NULL
°SPRIEITPS	NULL
``	NULL
'®	NULL
,	NULL
which	NULL
we	NULL
have	NULL
recently	NULL
shown	NULL
represents	NULL
a	NULL
docking	NULL
site	NULL
for	NULL
calcineurin	NULL
on	NULL
NFAT1	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Indeed	NULL
the	NULL
docking	NULL
sequence	NULL
is	NULL
present	NULL
in	NULL
both	NULL
short	NULL
NFAT1	NULL
fragments	NULL
,	NULL
(	NULL
97-144	NULL
)	NULL
and	NULL
(	NULL
97-183	NULL
)	NULL
,	NULL
that	NULL
are	NULL
capable	NULL
of	NULL
binding	NULL
to	NULL
calcineurin	NULL
,	NULL
but	NULL
absent	NULL
in	NULL
NFAT1	NULL
(	NULL
1-96	NULL
)	NULL
and	NULL
(	NULL
140-415	NULL
)	NULL
,	NULL
which	NULL
show	NULL
little	NULL
or	NULL
no	NULL
calcineurin	NULL
binding	NULL
,	NULL
confirming	NULL
that	NULL
the	NULL
docking	NULL
sequence	NULL
makes	NULL
a	NULL
major	NULL
contribution	NULL
to	NULL
the	NULL
NFAT-calcineurin	NULL
interac-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
23880	NULL
Interaction	NULL
of	NULL
Calcineurin	NULL
with	NULL
NFAT	NULL
++	NULL
.	NULL

A	NULL
Ca	NULL
B	NULL
CaM	NULL
C	NULL
_	NULL
Resistance	NULL
a	NULL
Independent	NULL
independent	NULL
to	NULL
CsA	NULL
``	NULL
g	NULL
[	NULL
4	NULL
EGTA	NULL
E	NULL
EGTA	NULL
§	NULL
3	NULL
a	NULL
150	NULL
®	NULL
n	NULL
Ca	NULL
-o	NULL
T	NULL
H	NULL
F	NULL
]	NULL
CypA	NULL
i	NULL
100	NULL
-	NULL
-	NULL
RN	NULL
CsA/CypA	NULL
4	NULL
'	NULL
100	NULL
2	NULL
_	NULL
&	NULL
-	NULL
___I	NULL
's	NULL
\	NULL
&	NULL
b	NULL
rarer	NULL
___I	NULL
k	NULL
oor	NULL
|	NULL
=	NULL
(	NULL
)	NULL
_	NULL
NFATI	NULL
NFAT2	NULL
LSF	NULL
D	NULL
Inhibited	NULL
by	NULL
AJ	NULL
or	NULL
RII	NULL
peptide	NULL
NFATIl	NULL
NFAT2	NULL
LSF	NULL
E	NULL
Inhibited	NULL
by	NULL
SPRIEIT	NULL
peptide	NULL
led	NULL
th	NULL
&	NULL
1	NULL
th	NULL
&	NULL
L	NULL
fmol	NULL
``	NULL
I-CnCAT	NULL
bound	NULL
Fi	NULL
NFAT2	NULL
SPAIAIA-25	NULL
e	NULL
SPRIEIT-25	NULL
0	NULL
100	NULL
_	NULL
200	NULL
_	NULL
300	NULL
Peptide	NULL
concentration	NULL
(	NULL
uM	NULL
)	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

NFAT	NULL
binds	NULL
to	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
.	NULL

A	NULL
and	NULL
B	NULL
,	NULL
'**I-CnCAT	NULL
(	NULL
4	NULL
nM	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
GST-NFAT1	NULL
,	NULL
GST-NFAT2	NULL
,	NULL
and	NULL
GST-LSF	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Ca**	NULL
or	NULL
EGTA	NULL
(	NULL
panel	NULL
A	NULL
)	NULL
,	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
EGTA	NULL
or	NULL
Ca**	NULL
and	NULL
calmodulin	NULL
(	NULL
CaM	NULL
)	NULL
(	NULL
pare	NULL
!	NULL

B	NULL
)	NULL
.	NULL

C	NULL
,	NULL
'**I-CnCAT	NULL
was	NULL
incubated	NULL
with	NULL
GST-NFAT2	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
-	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
1	NULL
uM	NULL
CypA	NULL
or	NULL
CsA	NULL
:	NULL
CypA	NULL
complexes	NULL
.	NULL

D	NULL
,	NULL
addition	NULL
of	NULL
autoinhibitory	NULL
(	NULL
AZ	NULL
)	NULL
or	NULL
RII	NULL
peptides	NULL
(	NULL
200	NULL
um	NULL
)	NULL
partially	NULL
inhibited	NULL
the	NULL
binding	NULL
of	NULL
'	NULL
``	NULL
I-CnCAT	NULL
to	NULL
GST-NFAT2	NULL
when	NULL
compared	NULL
with	NULL
binding	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
an	NULL
ovalbumin	NULL
peptide	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
(	NULL
-	NULL
)	NULL
.	NULL

Results	NULL
for	NULL
panels	NULL
A-D	NULL
are	NULL
shown	NULL
as	NULL
average	NULL
and	NULL
standard	NULL
deviations	NULL
of	NULL
a	NULL
representative	NULL
experiment	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

Note	NULL
that	NULL
error	NULL
bars	NULL
for	NULL
some	NULL
triplicates	NULL
are	NULL
too	NULL
small	NULL
to	NULL
be	NULL
apparent	NULL
.	NULL

£	NULL
,	NULL
the	NULL
peptide	NULL
SPRIEIT-25	NULL
spanning	NULL
the	NULL
calcineurin	NULL
docking	NULL
site	NULL
of	NULL
NFAT1	NULL
inhibited	NULL
binding	NULL
of	NULL
***I-CnCAT	NULL
to	NULL
NFAT	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
,	NULL
with	NULL
ICs	NULL
,	NULL
~	NULL
10	NULL
uM	NULL
,	NULL
whereas	NULL
the	NULL
mutant	NULL
SPAIAIA	NULL
peptide	NULL
had	NULL
no	NULL
effect	NULL
at	NULL
the	NULL
highest	NULL
concentration	NULL
used	NULL
.	NULL

tion	NULL
and	NULL
that	NULL
regions	NULL
outside	NULL
the	NULL
87-amino	NULL
acid	NULL
fragment	NULL
NFAT1	NULL
(	NULL
97-183	NULL
)	NULL
do	NULL
not	NULL
interact	NULL
effectively	NULL
with	NULL
calcineurin	NULL
.	NULL

NFAT	NULL
Binds	NULL
the	NULL
Calcineurin	NULL
Catalytic	NULL
Domain-To	NULL
define	NULL
the	NULL
region	NULL
of	NULL
calcineurin	NULL
involved	NULL
in	NULL
NFAT	NULL
binding	NULL
,	NULL
we	NULL
generated	NULL
a	NULL
recombinant	NULL
calcineurin	NULL
containing	NULL
only	NULL
the	NULL
catalytic	NULL
domain	NULL
(	NULL
residues	NULL
1-347	NULL
)	NULL
of	NULL
human	NULL
calcineurin	NULL
A	NULL
(	NULL
CnCAT	NULL
)	NULL
.	NULL

Despite	NULL
lacking	NULL
the	NULL
calcineurin	NULL
B-binding	NULL
helix	NULL
,	NULL
the	NULL
calmodu-lin-binding	NULL
region	NULL
and	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
,	NULL
this	NULL
protein	NULL
showed	NULL
substantial	NULL
binding	NULL
to	NULL
NFAT	NULL
(	NULL
Fig	NULL
.	NULL

3	NULL
)	NULL
.	NULL

Binding	NULL
of	NULL
**	NULL
``	NULL
I-CnCAT	NULL
to	NULL
GST-NFAT	NULL
was	NULL
equivalent	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
calcium	NULL
(	NULL
Fig	NULL
.	NULL

34	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
expectation	NULL
that	NULL
CnCAT	NULL
should	NULL
not	NULL
need	NULL
calcium	NULL
or	NULL
the	NULL
calcineurin	NULL
B	NULL
chain	NULL
to	NULL
assume	NULL
a	NULL
stable	NULL
protein	NULL
conformation	NULL
.	NULL

Binding	NULL
of	NULL
'*	NULL
``	NULL
I-CnCAT	NULL
to	NULL
GST-NFAT	NULL
was	NULL
also	NULL
equivalent	NULL
in	NULL
the	NULL
presence	NULL
and	NULL
absence	NULL
of	NULL
calmodulin	NULL
(	NULL
Fig	NULL
.	NULL

3B	NULL
)	NULL
,	NULL
consistent	NULL
with	NULL
the	NULL
fact	NULL
that	NULL
CnCAT	NULL
lacks	NULL
the	NULL
autoinhibitory	NULL
region	NULL
and	NULL
the	NULL
calmodulin-binding	NULL
domain	NULL
.	NULL

Finally	NULL
,	NULL
binding	NULL
of	NULL
**°I-CnrCAT	NULL
to	NULL
GST-NFAT	NULL
proteins	NULL
was	NULL
unaffected	NULL
by	NULL
drug-immunophilin	NULL
complexes	NULL
(	NULL
Fig	NULL
.	NULL

3C	NULL
)	NULL
,	NULL
which	NULL
are	NULL
not	NULL
expected	NULL
to	NULL
bind	NULL
CnCAT	NULL
since	NULL
they	NULL
bind	NULL
to	NULL
the	NULL
CnB-binding	NULL
helix	NULL
of	NULL
the	NULL
calcineurin	NULL
A-calcineurin	NULL
B	NULL
het-erodimer	NULL
,	NULL
which	NULL
is	NULL
lacking	NULL
in	NULL
CnCAT	NULL
.	NULL

The	NULL
use	NULL
of	NULL
inhibitory	NULL
peptides	NULL
defined	NULL
two	NULL
distinct	NULL
regions	NULL
for	NULL
NFAT	NULL
interaction	NULL
with	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
.	NULL

The	NULL
RII	NULL
substrate	NULL
peptide	NULL
and	NULL
the	NULL
calcineurin	NULL
autoinhibitory	NULL
domain	NULL
peptide	NULL
,	NULL
both	NULL
of	NULL
which	NULL
bind	NULL
to	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
in	NULL
their	NULL
unphosphorylated	NULL
forms	NULL
,	NULL
caused	NULL
significant	NULL
but	NULL
partial	NULL
inhibition	NULL
of	NULL
CnCAT	NULL
binding	NULL
to	NULL
NFAT	NULL
,	NULL
indicating	NULL
that	NULL
at	NULL
least	NULL
part	NULL
of	NULL
the	NULL
binding	NULL
involved	NULL
a	NULL
region	NULL
close	NULL
to	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
(	NULL
Fig	NULL
.	NULL

3D	NULL
)	NULL
.	NULL

Additionally	NULL
,	NULL
binding	NULL
was	NULL
inhibited	NULL
by	NULL
the	NULL
SPRIEIT-25	NULL
peptide	NULL
spanning	NULL
the	NULL
calcineurin	NULL
docking	NULL
site	NULL
of	NULL
NFAT1	NULL
(	NULL
Fig	NULL
.	NULL

36	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
complementary	NULL
surface	NULL
on	NULL
calcineurin	NULL
that	NULL
interacts	NULL
with	NULL
the	NULL
NFAT	NULL
SPRIEIT	NULL
sequence	NULL
is	NULL
present	NULL
within	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
.	NULL

Because	NULL
the	NULL
SPRIEIT	NULL
peptides	NULL
do	NULL
not	NULL
inhibit	NULL
calcineurin	NULL
phosphatase	NULL
activity	NULL
(	NULL
27	NULL
)	NULL
,	NULL
the	NULL
docking	NULL
region	NULL
for	NULL
NFAT	NULL
on	NULL
calcineurin	NULL
is	NULL
distinct	NULL
from	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
.	NULL

Thus	NULL
NFAT	NULL
binding	NULL
to	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
involves	NULL
at	NULL
least	NULL
two	NULL
regions	NULL
,	NULL
the	NULL
docking	NULL
site	NULL
on	NULL
NFAT	NULL
that	NULL
was	NULL
first	NULL
defined	NULL
using	NULL
inactive	NULL
calcineurin	NULL
(	NULL
27	NULL
)	NULL
,	NULL
and	NULL
a	NULL
region	NULL
overlapping	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
that	NULL
is	NULL
constitutively	NULL
exposed	NULL
in	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
.	NULL

In	NULL
the	NULL
following	NULL
sections	NULL
we	NULL
show	NULL
that	NULL
these	NULL
same	NULL
regions	NULL
are	NULL
involved	NULL
in	NULL
the	NULL
interaction	NULL
of	NULL
NFAT	NULL
with	NULL
calmod-	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
Interaction	NULL
of	NULL
Calcineurin	NULL
with	NULL
NFAT	NULL
23881	NULL
A	NULL
NFAT	NULL
200	NULL
150	NULL
SPRIEIT-25	NULL
-B-SPRIEIT-13	NULL
-G-E	NULL
100	NULL
SPAIAIA-25	NULL
-o-Fig	NULL
.	NULL

4	NULL
.	NULL

The	NULL
SPRIEIT	NULL
peptides	NULL
span-	NULL
3	NULL
ning	NULL
the	NULL
NFAT1	NULL
docking	NULL
site	NULL
for	NULL
cal-	NULL
g	NULL
50	NULL
cineurin	NULL
inhibit	NULL
the	NULL
binding	NULL
of	NULL
acti-	NULL
a	NULL
NFAT	NULL
mutant	NULL
vated	NULL
calcineurin	NULL
to	NULL
NFAT	NULL
.	NULL

'*°I-	NULL
+=	NULL
LSF	NULL
Calcineurin	NULL
(	NULL
14	NULL
nM	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
=	NULL
)	NULL
0	NULL
(	NULL
A	NULL
)	NULL
GST-NFAT1	NULL
or	NULL
(	NULL
B	NULL
)	NULL
GST-NFAT2	NULL
or	NULL
@	NULL
A	NULL
!	NULL

!	NULL
'	NULL

'	NULL
GST-NFAT4	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
Ca	NULL
``	NULL
*	NULL
and	NULL
.5	NULL
0	NULL
25	NULL
50	NULL
75	NULL
100	NULL
125	NULL
calmodulin	NULL
and	NULL
the	NULL
indicated	NULL
concentra-	NULL
LS	NULL
B	NULL
tions	NULL
of	NULL
the	NULL
SPRIEIT-25	NULL
,	NULL
SPRIEIT-13	NULL
,	NULL
G	NULL
and	NULL
SPAIAIA-25	NULL
peptides	NULL
.	NULL

A	NULL
also	NULL
shows	NULL
2	NULL
NFAT2	NULL
NFAT4A	NULL
the	NULL
level	NULL
of	NULL
binding	NULL
to	NULL
a	NULL
&	NULL
mutant	NULL
GST-NFAT1	NULL
bearing	NULL
the	NULL
SPAI-	NULL
-	NULL
500	NULL
AIA	NULL
mutation	NULL
(	NULL
R112A	NULL
,	NULL
E114A	NULL
,	NULL
T116A	NULL
)	NULL
in	NULL
0	NULL
the	NULL
docking	NULL
sequence	NULL
.	NULL

The	NULL
level	NULL
of	NULL
non-	NULL
[	NULL
=	NULL
400	NULL
specific	NULL
binding	NULL
of	NULL
calcineurin	NULL
was	NULL
moni-	NULL
w=	NULL
40	NULL
tored	NULL
by	NULL
its	NULL
binding	NULL
to	NULL
GST-LSF	NULL
(	NULL
LSF	NULL
)	NULL
.	NULL

7	NULL
300	NULL
200	NULL
100	NULL
LSF	NULL
LSF	NULL
0	NULL
T	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
25	NULL
50	NULL
75	NULL
100	NULL
125	NULL
0	NULL
25	NULL
50	NULL
75	NULL
100	NULL
125	NULL
Peptide	NULL
concentration	NULL
(	NULL
uM	NULL
)	NULL
A	NULL
-	NULL
Calmodulin-activated	NULL
B	NULL
Inactive	NULL
Calcineurin	NULL
Calcineurin	NULL
150	NULL
G3	NULL
|	NULL
Fic	NULL
.	NULL

5	NULL
.	NULL

Inhibition	NULL
of	NULL
the	NULL
NFAT-cal-fad	NULL
125	NULL
cineurin	NULL
interaction	NULL
by	NULL
drug-immu-3	NULL
nophilin	NULL
complexes	NULL
.	NULL

'**I-Calcineurin	NULL
g	NULL
100	NULL
T	NULL
7	NULL
(	NULL
Cn	NULL
)	NULL
(	NULL
10	NULL
nM	NULL
)	NULL
was	NULL
incubated	NULL
with	NULL
LNT	NULL
NFAT1	NULL
(	NULL
Q7-183	NULL
)	NULL
and	NULL
the	NULL
indicated	NULL
con-5	NULL
75	NULL
a-	NULL
_	NULL
centrations	NULL
of	NULL
preformed	NULL
FK506-FKBP12	NULL
r	NULL
complexes	NULL
in	NULL
the	NULL
presence	NULL
(	NULL
A	NULL
)	NULL
or	NULL
absence	NULL
2m—	NULL
yi	NULL
(	NULL
B	NULL
)	NULL
of	NULL
Ca	NULL
``	NULL
*	NULL
and	NULL
calmodulin	NULL
.	NULL

The	NULL
average	NULL
G	NULL
50	NULL
+-	NULL
Nr	NULL
T	NULL
and	NULL
standard	NULL
deviation	NULL
for	NULL
four	NULL
independ-E	NULL
4.	NULL
am	NULL
ent	NULL
experiments	NULL
is	NULL
shown	NULL
.	NULL

Note	NULL
that	NULL
error	NULL
2	NULL
25	NULL
-	NULL
=	NULL
bars	NULL
for	NULL
some	NULL
quadruplicates	NULL
are	NULL
too	NULL
small	NULL
to	NULL
be	NULL
apparent	NULL
.	NULL

0	NULL
4	NULL
T	NULL
T	NULL
0	NULL
001	NULL
o1	NULL
4	NULL
do	NULL
doo	NULL
00.01	NULL
O10	NULL
d	NULL
FK506/FKBP12	NULL
concentration	NULL
(	NULL
uM	NULL
)	NULL
ulin-activated	NULL
calcineurin	NULL
.	NULL

Peptides	NULL
Spanning	NULL
the	NULL
NFAT	NULL
Docking	NULL
Sequence	NULL
Inhibit	NULL
the	NULL
Binding	NULL
of	NULL
Activated	NULL
Calcineurin	NULL
to	NULL
NFAT-The	NULL
SPAIATA	NULL
mutation	NULL
in	NULL
the	NULL
SPRIEIT	NULL
docking	NULL
sequence	NULL
(	NULL
R112A	NULL
,	NULL
Ell4A	NULL
,	NULL
T116A	NULL
)	NULL
impaired	NULL
not	NULL
only	NULL
the	NULL
basal	NULL
binding	NULL
of	NULL
NFAT1	NULL
to	NULL
inactive	NULL
calcineurin	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
calmodulin	NULL
(	NULL
27	NULL
)	NULL
,	NULL
but	NULL
also	NULL
the	NULL
calmodulin-dependent	NULL
binding	NULL
of	NULL
activated	NULL
calcineurin	NULL
to	NULL
NFAT	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
.	NULL

Moreover	NULL
the	NULL
peptides	NULL
SPRIEIT-25	NULL
and	NULL
SPRIEIT-13	NULL
spanning	NULL
25	NULL
and	NULL
13	NULL
residues	NULL
of	NULL
this	NULL
docking	NULL
sequence	NULL
competed	NULL
the	NULL
binding	NULL
of	NULL
activated	NULL
calcineurin	NULL
to	NULL
NFATI	NULL
(	NULL
I-415	NULL
)	NULL
,	NULL
whereas	NULL
the	NULL
peptide	NULL
SPAIAIA-25	NULL
,	NULL
which	NULL
incorporated	NULL
the	NULL
inactivating	NULL
mutations	NULL
,	NULL
did	NULL
not	NULL
(	NULL
Fig	NULL
.	NULL

44	NULL
)	NULL
.	NULL

The	NULL
concentration	NULL
of	NULL
SPRIEIT	NULL
peptides	NULL
required	NULL
for	NULL
half-maximal	NULL
inhibition	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
activated	NULL
calcineurin	NULL
to	NULL
was	NULL
~25	NULL
un	NULL
(	NULL
Fig	NULL
.	NULL

4A	NULL
)	NULL
,	NULL
compared	NULL
with	NULL
the	NULL
~12	NULL
uM	NULL
required	NULL
for	NULL
half-maximal	NULL
inhibition	NULL
of	NULL
the	NULL
binding	NULL
of	NULL
inactive	NULL
calcineurin	NULL
to	NULL
NFAT	NULL
(	NULL
27	NULL
)	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
activated	NULL
calcineurin	NULL
to	NULL
NFAT2	NULL
and	NULL
NFAT4	NULL
was	NULL
also	NULL
inhibited	NULL
by	NULL
the	NULL
SPRIEIT	NULL
peptides	NULL
(	NULL
Fig	NULL
.	NULL

4B	NULL
)	NULL
with	NULL
an	NULL
IC	NULL
;	NULL
5	NULL
,	NULL
of	NULL
~50	NULL
uM	NULL
,	NULL
again	NULL
a	NULL
higher	NULL
concentration	NULL
than	NULL
necessary	NULL
to	NULL
inhibit	NULL
the	NULL
binding	NULL
of	NULL
inactive	NULL
calcineurin	NULL
to	NULL
these	NULL
proteins	NULL
(	NULL
IC	NULL
;	NULL
,	NULL
of	NULL
~25	NULL
um	NULL
)	NULL
(	NULL
27	NULL
)	NULL
.	NULL

SPRIEIT	NULL
peptides	NULL
were	NULL
also	NULL
able	NULL
to	NULL
inhibit	NULL
binding	NULL
of	NULL
active	NULL
and	NULL
inactive	NULL
calcineurin	NULL
to	NULL
the	NULL
short	NULL
NFAT1	NULL
fragment	NULL
(	NULL
97-183	NULL
)	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Drug-Immunophilin	NULL
Complexes	NULL
Partially	NULL
Inhibit	NULL
the	NULL
Binding	NULL
of	NULL
Activated	NULL
Calcineurin	NULL
to	NULL
NFAT-To	NULL
determine	NULL
whether	NULL
NFAT	NULL
binding	NULL
to	NULL
active	NULL
calcineurin	NULL
involved	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
,	NULL
we	NULL
tested	NULL
the	NULL
effect	NULL
of	NULL
FK506-FKBP12	NULL
complexes	NULL
on	NULL
the	NULL
binding	NULL
of	NULL
active	NULL
(	NULL
calmodulin-dependent	NULL
)	NULL
and	NULL
inactive	NULL
calcineurin	NULL
to	NULL
NFAT1	NULL
(	NULL
97-183	NULL
)	NULL
.	NULL

In	NULL
both	NULL
cases	NULL
binding	NULL
was	NULL
inhibited	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
by	NULL
the	NULL
drug-immunophilin	NULL
complexes	NULL
,	NULL
but	NULL
the	NULL
extent	NULL
of	NULL
inhibition	NULL
was	NULL
much	NULL
greater	NULL
in	NULL
the	NULL
case	NULL
of	NULL
active	NULL
compared	NULL
with	NULL
inactive	NULL
calcineurin	NULL
(	NULL
~80	NULL
%	NULL
versus	NULL
~50	NULL
%	NULL
inhibition	NULL
at	NULL
10	NULL
um	NULL
FK506GFKBP12	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
compare	NULL
panels	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
approximately	NULL
10-fold	NULL
higher	NULL
con	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
23882	NULL
GST-NFAT2	NULL
(	NULL
1-418	NULL
)	NULL
+	NULL
On	NULL
Cn	NULL
Wt	NULL
H151A	NULL
CaM	NULL
z	NULL
=	NULL
--	NULL
@	NULL
10	NULL
20	NULL
3	NULL
4	NULL
Fig	NULL
.	NULL

6	NULL
.	NULL

The	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
is	NULL
not	NULL
required	NULL
for	NULL
binding	NULL
to	NULL
NFAT	NULL
.	NULL

The	NULL
binding	NULL
of	NULL
recombinant	NULL
wild-type	NULL
(	NULL
W¢	NULL
)	NULL
calcineurin	NULL
or	NULL
the	NULL
catalytically	NULL
inactive	NULL
His	NULL
``	NULL
-	NULL
>	NULL
Ala	NULL
mutant	NULL
(	NULL
H151A	NULL
)	NULL
to	NULL
GST-NFAT2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
calmodulin	NULL
was	NULL
assessed	NULL
by	NULL
Western	NULL
blotting	NULL
.	NULL

centrations	NULL
of	NULL
FK506-FKBP12	NULL
were	NULL
required	NULL
to	NULL
achieve	NULL
equivalent	NULL
inhibition	NULL
of	NULL
inactive	NULL
versus	NULL
active	NULL
calcineurin	NULL
(	NULL
.e	NULL
.	NULL

0.1	NULL
uM	NULL
FK506-FKBP12	NULL
sufficed	NULL
to	NULL
inhibit	NULL
binding	NULL
of	NULL
active	NULL
calcineurin	NULL
by	NULL
30	NULL
%	NULL
,	NULL
whereas	NULL
1	NULL
um	NULL
FK506	NULL
:	NULL
FKBP12	NULL
was	NULL
required	NULL
for	NULL
equivalent	NULL
inhibition	NULL
of	NULL
binding	NULL
of	NULL
inactive	NULL
calcineurin	NULL
to	NULL
NFAT	NULL
;	NULL
compare	NULL
Fig	NULL
.	NULL

5	NULL
,	NULL
A	NULL
and	NULL
B	NULL
)	NULL
.	NULL

The	NULL
immunophilins	NULL
CyPA	NULL
and	NULL
FKBP12	NULL
had	NULL
no	NULL
effect	NULL
on	NULL
the	NULL
NFAT-calcineurin	NULL
in	NULL
the	NULL
absence	NULL
of	NULL
the	NULL
relevant	NULL
immunosupressive	NULL
drugs	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

The	NULL
Catalytic	NULL
Activity	NULL
of	NULL
Calcineurin	NULL
Is	NULL
Not	NULL
Required	NULL
for	NULL
NFAT-Calcineurin	NULL
Binding-Since	NULL
the	NULL
previous	NULL
experiments	NULL
implicated	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
in	NULL
NFAT-calcineurin	NULL
binding	NULL
,	NULL
we	NULL
asked	NULL
whether	NULL
the	NULL
catalytic	NULL
activity	NULL
of	NULL
calcineurin	NULL
was	NULL
required	NULL
for	NULL
binding	NULL
to	NULL
NFAT	NULL
proteins	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

Recombinant	NULL
wild-type	NULL
calcineurin	NULL
or	NULL
the	NULL
inactive	NULL
His	NULL
``	NULL
-	NULL
Ala	NULL
mutant	NULL
were	NULL
incubated	NULL
with	NULL
GST-NFAT2	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
calmodulin	NULL
.	NULL

The	NULL
beads	NULL
were	NULL
then	NULL
washed	NULL
and	NULL
the	NULL
amount	NULL
of	NULL
bound	NULL
calcineurin	NULL
was	NULL
assessed	NULL
by	NULL
Western	NULL
blotting	NULL
with	NULL
an	NULL
antibody	NULL
to	NULL
the	NULL
autoinhibitory	NULL
peptide	NULL
of	NULL
calcineurin	NULL
A	NULL
,	NULL
exactly	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
15	NULL
)	NULL
.	NULL

Fig	NULL
.	NULL

5	NULL
shows	NULL
that	NULL
there	NULL
was	NULL
equivalent	NULL
binding	NULL
of	NULL
the	NULL
catalytically	NULL
active	NULL
and	NULL
inactive	NULL
calcineurin	NULL
to	NULL
NFAT	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
NFAT-calcineurin	NULL
interaction	NULL
does	NULL
not	NULL
require	NULL
the	NULL
phosphatase	NULL
activity	NULL
of	NULL
calcineurin	NULL
.	NULL

Consistent	NULL
with	NULL
this	NULL
result	NULL
,	NULL
catalytically	NULL
inactive	NULL
calcineurins	NULL
,	NULL
when	NULL
overexpressed	NULL
,	NULL
inhibited	NULL
the	NULL
nuclear	NULL
import	NULL
of	NULL
NFAT4	NULL
(	NULL
16	NULL
)	NULL
,	NULL
indicating	NULL
that	NULL
these	NULL
proteins	NULL
remained	NULL
capable	NULL
of	NULL
interaction	NULL
with	NULL
NFAT	NULL
.	NULL

Characteristics	NULL
of	NULL
the	NULL
NFAT-Calcineurin	NULL
Interaction-The	NULL
NFAT-calcineurin	NULL
interaction	NULL
is	NULL
central	NULL
to	NULL
the	NULL
proper	NULL
regulation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
(	NULL
6	NULL
,	NULL
35	NULL
)	NULL
,	NULL
and	NULL
also	NULL
plays	NULL
a	NULL
role	NULL
in	NULL
the	NULL
function	NULL
of	NULL
cells	NULL
and	NULL
tissues	NULL
outside	NULL
the	NULL
immune	NULL
system	NULL
(	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
calmodulin-activated	NULL
calcineurin	NULL
binds	NULL
significantly	NULL
more	NULL
strongly	NULL
than	NULL
does	NULL
inactive	NULL
calcineurin	NULL
to	NULL
NFAT	NULL
.	NULL

The	NULL
interacting	NULL
regions	NULL
are	NULL
located	NULL
on	NULL
the	NULL
catalytic	NULL
domain	NULL
of	NULL
the	NULL
calcineurin	NULL
A	NULL
chain	NULL
and	NULL
on	NULL
an	NULL
86-amino	NULL
acid	NULL
fragment	NULL
of	NULL
the	NULL
NFAT	NULL
regulatory	NULL
domain	NULL
.	NULL

Our	NULL
results	NULL
suggest	NULL
that	NULL
the	NULL
interaction	NULL
of	NULL
activated	NULL
calcineurin	NULL
with	NULL
NFAT	NULL
involves	NULL
at	NULL
least	NULL
two	NULL
functionally	NULL
separable	NULL
regions	NULL
.	NULL

One	NULL
of	NULL
these	NULL
is	NULL
the	NULL
SPRIEIT	NULL
sequence	NULL
of	NULL
NFAT1	NULL
,	NULL
which	NULL
we	NULL
have	NULL
previously	NULL
identified	NULL
as	NULL
the	NULL
docking	NULL
site	NULL
for	NULL
inactive	NULL
calcineurin	NULL
in	NULL
resting	NULL
cells	NULL
(	NULL
27	NULL
)	NULL
,	NULL
while	NULL
the	NULL
second	NULL
involves	NULL
the	NULL
enzyme	NULL
active	NULL
site	NULL
.	NULL

The	NULL
active	NULL
site	NULL
interaction	NULL
is	NULL
inhibited	NULL
by	NULL
the	NULL
calcineurin	NULL
autoinhibitory	NULL
domain	NULL
and	NULL
the	NULL
RII	NULL
substrate	NULL
peptide	NULL
,	NULL
which	NULL
bind	NULL
in	NULL
the	NULL
active	NULL
site	NULL
,	NULL
as	NULL
well	NULL
as	NULL
by	NULL
drug-immunophilin	NULL
complexes	NULL
that	NULL
partially	NULL
occlude	NULL
the	NULL
active	NULL
site	NULL
.	NULL

The	NULL
active	NULL
site	NULL
contact	NULL
appears	NULL
to	NULL
make	NULL
a	NULL
substantially	NULL
stronger	NULL
contribution	NULL
to	NULL
the	NULL
NFAT-calcineurin	NULL
interaction	NULL
under	NULL
stimulatory	NULL
conditions	NULL
,	NULL
when	NULL
the	NULL
calcineurin	NULL
has	NULL
been	NULL
activated	NULL
with	NULL
calcium	NULL
and	NULL
calmodulin	NULL
.	NULL

These	NULL
results	NULL
shed	NULL
light	NULL
on	NULL
previous	NULL
findings	NULL
in	NULL
which	NULL
calcineurin	NULL
was	NULL
shown	NULL
to	NULL
coprecipitate	NULL
with	NULL
NFAT4	NULL
in	NULL
cell	NULL
lysates	NULL
only	NULL
after	NULL
activation	NULL
of	NULL
the	NULL
cells	NULL
(	NULL
16	NULL
)	NULL
.	NULL

It	NULL
is	NULL
likely	NULL
that	NULL
the	NULL
Western	NULL
blotting	NULL
assay	NULL
used	NULL
was	NULL
insensitive	NULL
and	NULL
permitted	NULL
detection	NULL
of	NULL
the	NULL
NFAT4-calcineurin	NULL
interaction	NULL
only	NULL
under	NULL
conditions	NULL
of	NULL
calcineurin	NULL
activation	NULL
.	NULL

In	NULL
other	NULL
work	NULL
,	NULL
cells	NULL
were	NULL
not	NULL
previously	NULL
activated	NULL
,	NULL
but	NULL
coprecipitation	NULL
of	NULL
NFAT	NULL
and	NULL
calcineurin	NULL
was	NULL
assessed	NULL
using	NULL
calcineurin	NULL
bound	NULL
to	NULL
calmodulin	NULL
beads	NULL
(	NULL
13	NULL
,	NULL
26	NULL
)	NULL
,	NULL
or	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
calcium	NULL
concentrations	NULL
that	NULL
Interaction	NULL
of	NULL
Calcineurin	NULL
with	NULL
NFAT	NULL
allowed	NULL
activation	NULL
by	NULL
calmodulin	NULL
in	NULL
the	NULL
cell	NULL
lysates	NULL
(	NULL
17	NULL
)	NULL
.	NULL

Given	NULL
the	NULL
fact	NULL
that	NULL
activated	NULL
(	NULL
dephosphorylated	NULL
)	NULL
as	NULL
well	NULL
as	NULL
inactive	NULL
(	NULL
phosphorylated	NULL
)	NULL
NFAT	NULL
bind	NULL
equivalently	NULL
to	NULL
calcineurin	NULL
(	NULL
13	NULL
,	NULL
26	NULL
)	NULL
,	NULL
the	NULL
increased	NULL
binding	NULL
seen	NULL
under	NULL
conditions	NULL
of	NULL
cell	NULL
activation	NULL
reflects	NULL
the	NULL
significant	NULL
increase	NULL
in	NULL
NFAT	NULL
binding	NULL
to	NULL
calcineurin	NULL
in	NULL
the	NULL
activated	NULL
state	NULL
.	NULL

Analysis	NULL
of	NULL
deletion	NULL
mutants	NULL
of	NULL
NFAT4	NULL
suggested	NULL
that	NULL
NFAT	NULL
possessed	NULL
multiple	NULL
regions	NULL
of	NULL
interaction	NULL
with	NULL
calcineurin	NULL
(	NULL
17	NULL
)	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
our	NULL
data	NULL
with	NULL
both	NULL
NFAT1	NULL
and	NULL
NFAT4	NULL
emphasize	NULL
the	NULL
importance	NULL
of	NULL
the	NULL
SPRIEIT	NULL
docking	NULL
sequence	NULL
in	NULL
the	NULL
NFAT-calcineurin	NULL
interaction	NULL
,	NULL
and	NULL
point	NULL
to	NULL
a	NULL
major	NULL
involvement	NULL
of	NULL
the	NULL
(	NULL
97-183	NULL
)	NULL
fragment	NULL
of	NULL
NFAT1	NULL
.	NULL

Nevertheless	NULL
the	NULL
truncation	NULL
mutants	NULL
NFAT1	NULL
(	NULL
I1-96	NULL
)	NULL
and	NULL
NFATI1	NULL
(	NULL
140-415	NULL
)	NULL
showed	NULL
weak	NULL
calmodulin-dependent	NULL
binding	NULL
to	NULL
calcineurin	NULL
,	NULL
suggesting	NULL
that	NULL
regions	NULL
outside	NULL
the	NULL
SPRIEIT	NULL
sequence	NULL
and	NULL
the	NULL
(	NULL
97-183	NULL
)	NULL
region	NULL
might	NULL
contribute	NULL
to	NULL
calcineurin	NULL
binding	NULL
.	NULL

This	NULL
may	NULL
be	NULL
particularly	NULL
true	NULL
for	NULL
NFAT4	NULL
.	NULL

Based	NULL
on	NULL
our	NULL
data	NULL
,	NULL
we	NULL
propose	NULL
a	NULL
model	NULL
for	NULL
the	NULL
interaction	NULL
of	NULL
calcineurin	NULL
with	NULL
NFAT	NULL
proteins	NULL
in	NULL
resting	NULL
and	NULL
activated	NULL
cells	NULL
.	NULL

We	NULL
suggest	NULL
that	NULL
NFAT	NULL
is	NULL
targeted	NULL
to	NULL
inactive	NULL
calcineurin	NULL
via	NULL
the	NULL
SPRIEIT	NULL
docking	NULL
sequence	NULL
(	NULL
and	NULL
possibly	NULL
other	NULL
regions	NULL
within	NULL
the	NULL
(	NULL
97-183	NULL
)	NULL
NFAT1	NULL
fragment	NULL
)	NULL
.	NULL

This	NULL
targeting	NULL
interaction	NULL
involves	NULL
a	NULL
region	NULL
of	NULL
the	NULL
calcineurin	NULL
catalytic	NULL
domain	NULL
that	NULL
does	NULL
not	NULL
overlap	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
and	NULL
ensures	NULL
the	NULL
proximity	NULL
of	NULL
the	NULL
enzyme	NULL
to	NULL
its	NULL
substrate	NULL
in	NULL
resting	NULL
cells	NULL
.	NULL

Upon	NULL
cell	NULL
activation	NULL
,	NULL
displacement	NULL
of	NULL
the	NULL
autoinhibitory	NULL
domain	NULL
of	NULL
calcineurin	NULL
by	NULL
calmodulin	NULL
allows	NULL
NFAT	NULL
to	NULL
bind	NULL
additionally	NULL
to	NULL
the	NULL
calcineurin	NULL
active	NULL
site	NULL
,	NULL
positioning	NULL
specific	NULL
regulatory	NULL
phosphoserine	NULL
residues	NULL
of	NULL
NFAT	NULL
for	NULL
immediate	NULL
dephosphorylation	NULL
.	NULL

Further	NULL
analysis	NULL
of	NULL
this	NULL
dynamic	NULL
interaction	NULL
will	NULL
facilitate	NULL
our	NULL
understanding	NULL
of	NULL
how	NULL
calcineurin	NULL
regulates	NULL
NFAT-mediated	NULL
gene	NULL
transcription	NULL
.	NULL

Moreover	NULL
it	NULL
may	NULL
speed	NULL
the	NULL
development	NULL
of	NULL
new	NULL
immunosuppressive	NULL
drugs	NULL
that	NULL
block	NULL
the	NULL
NFAT-calcineurin	NULL
interaction	NULL
but	NULL
lack	NULL
the	NULL
deleterious	NULL
site	NULL
effects	NULL
of	NULL
cyclosporin	NULL
A	NULL
and	NULL
FK506	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Drs	NULL
.	NULL

Jun	NULL
Liu	NULL
,	NULL
Brian	NULL
Perrino	NULL
,	NULL
Fernando	NULL
Macian	NULL
,	NULL
Christopher	NULL
Walsh	NULL
,	NULL
and	NULL
Patrick	NULL
Hogan	NULL
for	NULL
gifts	NULL
of	NULL
reagents	NULL
and	NULL
many	NULL
helpful	NULL
discussions	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Luo	NULL
,	NULL
C.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Badalian	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Burgeon	NULL
,	NULL
E.	NULL
,	NULL
Lane	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Lambert	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
Science	NULL
262	NULL
,	NULL
750-754	NULL
2	NULL
.	NULL

Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
Chen	NULL
,	NULL
L.	NULL
,	NULL
Thomas	NULL
,	NULL
D.	NULL
J.	NULL
,	NULL
Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Nolan	NULL
,	NULL
G.	NULL
P.	NULL
,	NULL
Admon	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1994	NULL
)	NULL
Nature	NULL
869	NULL
,	NULL
497-502	NULL
3	NULL
.	NULL

Masuda	NULL
,	NULL
E.	NULL
,	NULL
Naito	NULL
,	NULL
Y.	NULL
,	NULL
Tokumitsu	NULL
,	NULL
H.	NULL
,	NULL
Campbell	NULL
,	NULL
D.	NULL
,	NULL
Saito	NULL
,	NULL
F.	NULL
,	NULL
Hannum	NULL
,	NULL
C.	NULL
,	NULL
Arai	NULL
,	NULL
K.-L.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1995	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

15	NULL
,	NULL
2697-2706	NULL
.	NULL

Hoey	NULL
,	NULL
T.	NULL
,	NULL
Sun	NULL
,	NULL
Y.	NULL
L.	NULL
,	NULL
Williamson	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Xu	NULL
,	NULL
X	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Immunity	NULL
2	NULL
,	NULL
461-472	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
Burgeon	NULL
,	NULL
E.	NULL
,	NULL
Carew	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Badalian	NULL
,	NULL
T.	NULL
M.	NULL
,	NULL
Lane	NULL
,	NULL
W.	NULL
S.	NULL
,	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
8955-3966	NULL
.	NULL

Rao	NULL
,	NULL
A.	NULL
,	NULL
Luo	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1997	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Immunol	NULL
.	NULL

15	NULL
,	NULL
707-747	NULL
.	NULL

Shaw	NULL
,	NULL
K.	NULL
T.	NULL
,	NULL
Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Raghavan	NULL
,	NULL
A.	NULL
,	NULL
Kim	NULL
,	NULL
J.	NULL
,	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Park	NULL
,	NULL
J.	NULL
,	NULL
Sharma	NULL
,	NULL
S.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1995	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

92	NULL
,	NULL
11205-11209	NULL
8	NULL
.	NULL

Aramburu	NULL
,	NULL
J.	NULL
,	NULL
Azzoni	NULL
,	NULL
L.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Perussia	NULL
,	NULL
B	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

182	NULL
,	NULL
801-810	NULL
9	NULL
.	NULL

Cockerill	NULL
,	NULL
G.	NULL
W.	NULL
,	NULL
Bert	NULL
,	NULL
A.	NULL
G.	NULL
,	NULL
Ryan	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
Gamble	NULL
,	NULL
J.	NULL
R.	NULL
,	NULL
Vadas	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
and	NULL
Cockerill	NULL
,	NULL
P.	NULL
N.	NULL
(	NULL
1995	NULL
)	NULL
Blood	NULL
86	NULL
,	NULL
2689-2698	NULL
10	NULL
.	NULL

Ho	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

269	NULL
,	NULL
28181-28186	NULL
11	NULL
.	NULL

Delapompa	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Takimoto	NULL
,	NULL
H.	NULL
,	NULL
Yoshida	NULL
,	NULL
H.	NULL
,	NULL
Elia	NULL
,	NULL
A.	NULL
J.	NULL
,	NULL
Samper	NULL
,	NULL
E.	NULL
,	NULL
Potter	NULL
,	NULL
J.	NULL
,	NULL
Wakeham	NULL
,	NULL
A.	NULL
,	NULL
Marengere	NULL
,	NULL
L.	NULL
,	NULL
Langille	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Mak	NULL
,	NULL
T.	NULL
W.	NULL
(	NULL
1998	NULL
)	NULL
Nature	NULL
892	NULL
,	NULL
182-186	NULL
12	NULL
.	NULL

Ranger	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Grusby	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Hodge	NULL
,	NULL
M.	NULL
R.	NULL
,	NULL
Gravallese	NULL
,	NULL
E.	NULL
M.	NULL
,	NULL
Delabrousse	NULL
,	NULL
F.	NULL
C.	NULL
,	NULL
Hoey	NULL
,	NULL
T.	NULL
,	NULL
Mickanin	NULL
,	NULL
C.	NULL
,	NULL
Baldwin	NULL
,	NULL
H.	NULL
S.	NULL
,	NULL
and	NULL
Glimcher	NULL
,	NULL
L.	NULL
H.	NULL
(	NULL
1998	NULL
)	NULL
Nature	NULL
892	NULL
,	NULL
186-190	NULL
13	NULL
.	NULL

Lob	NULL
,	NULL
C.	NULL
,	NULL
Shaw	NULL
,	NULL
K.	NULL
T.	NULL
,	NULL
Carew	NULL
,	NULL
J.	NULL
,	NULL
Viola	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Luo	NULL
,	NULL
C.	NULL
,	NULL
Perrino	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
10884-10891	NULL
14	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
Burgeon	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996b	NULL
)	NULL
J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

184	NULL
,	NULL
141-147	NULL
15	NULL
.	NULL

Luo	NULL
,	NULL
C.	NULL
,	NULL
Shaw	NULL
,	NULL
K.	NULL
T.	NULL
,	NULL
Raghavan	NULL
,	NULL
A.	NULL
,	NULL
Aramburu	NULL
,	NULL
J.	NULL
,	NULL
Garcia-Cozar	NULL
,	NULL
F.	NULL
,	NULL
Perrino	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
8907-8912	NULL
16	NULL
.	NULL

Shibasaki	NULL
,	NULL
F.	NULL
,	NULL
Price	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
Milan	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
McKeon	NULL
,	NULL
F.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
382	NULL
,	NULL
370-373	NULL
17	NULL
.	NULL

Masuda	NULL
,	NULL
E.	NULL
S.	NULL
,	NULL
Liu	NULL
,	NULL
J.	NULL
,	NULL
Imamura	NULL
,	NULL
R.	NULL
,	NULL
Imai	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
Arai	NULL
,	NULL
K.	NULL
L.	NULL
,	NULL
and	NULL
Arai	NULL
,	NULL
N.	NULL
(	NULL
1997	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

17	NULL
,	NULL
2066-2075	NULL
18	NULL
.	NULL

Beals	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1997	NULL
)	NULL
Genes	NULL
Dev	NULL
.	NULL

gigs	NULL
~	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23.	NULL
.	NULL

Chen	NULL
,	NULL
L.	NULL
,	NULL
Glover	NULL
,	NULL
J.	NULL
N.	NULL
M.	NULL
,	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Harrison	NULL
,	NULL
S.	NULL
C.	NULL
(	NULL
1998	NULL
)	NULL
25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

Interaction	NULL
of	NULL
Calcineurin	NULL
with	NULL
NFAT	NULL
11	NULL
,	NULL
824-	NULL
834	NULL
Loh	NULL
,	NULL
C.	NULL
,	NULL
Carew	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Kim	NULL
,	NULL
J.	NULL
,	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
3945-3954	NULL
Timmerman	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Clipstone	NULL
,	NULL
N.	NULL
A.	NULL
,	NULL
Ho	NULL
,	NULL
S.	NULL
N.	NULL
,	NULL
Northrop	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1996	NULL
)	NULL
Nature	NULL
388	NULL
,	NULL
837-840	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Valge-Archer	NULL
,	NULL
V.	NULL
E.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
Nature	NULL
856	NULL
,	NULL
801-803	NULL
Jain	NULL
,	NULL
J.	NULL
,	NULL
McCaffrey	NULL
,	NULL
P.	NULL
G.	NULL
,	NULL
Miner	NULL
,	NULL
Z.	NULL
,	NULL
Kerppola	NULL
,	NULL
T.	NULL
K.	NULL
,	NULL
Lambert	NULL
,	NULL
J.	NULL
N.	NULL
,	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
,	NULL
Curran	NULL
,	NULL
T.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Nature	NULL
865	NULL
,	NULL
852-855	NULL
Chytil	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Verdine	NULL
,	NULL
G.	NULL
L.	NULL
(	NULL
1996	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Struct	NULL
.	NULL

Biol	NULL
.	NULL

6	NULL
,	NULL
91-100	NULL
Nature	NULL
892	NULL
,	NULL
42-48	NULL
Klee	NULL
,	NULL
C.	NULL
B.	NULL
,	NULL
Dractta	NULL
,	NULL
G.	NULL
F.	NULL
,	NULL
and	NULL
Hubbard	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Adv	NULL
.	NULL

Enzymol	NULL
.	NULL

61	NULL
,	NULL
149-200	NULL
Wesselborg	NULL
,	NULL
S.	NULL
,	NULL
Fruman	NULL
,	NULL
D.	NULL
A.	NULL
,	NULL
Sagoo	NULL
,	NULL
J.	NULL
K.	NULL
,	NULL
Bicrer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
1274-1277	NULL
Aramburu	NULL
,	NULL
J.	NULL
,	NULL
Garcia-Cozar	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Raghavan	NULL
,	NULL
A.	NULL
,	NULL
Okamura	NULL
,	NULL
H.	NULL
,	NULL
Rao	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Hogan	NULL
,	NULL
P.	NULL
G.	NULL
(	NULL
1998	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
1	NULL
,	NULL
627-637	NULL
Sikkink	NULL
,	NULL
R.	NULL
,	NULL
Haddy	NULL
,	NULL
A.	NULL
,	NULL
MacKelvie	NULL
,	NULL
S.	NULL
,	NULL
Mertz	NULL
,	NULL
P.	NULL
,	NULL
Litwiller	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Rusnak	NULL
,	NULL
F.	NULL
(	NULL
1995	NULL
)	NULL
Biochemistry	NULL
34	NULL
,	NULL
8848-8356	NULL
Manalan	NULL
,	NULL
A.	NULL
,	NULL
and	NULL
Klee	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1983	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

80	NULL
,	NULL
4291-4295	NULL
Hubbard	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
and	NULL
Klee	NULL
,	NULL
C.	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Biochemistry	NULL
28	NULL
,	NULL
1868-1874	NULL
31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34.	NULL
.	NULL

Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
,	NULL
and	NULL
Clipstone	NULL
,	NULL
N.	NULL
A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Annu	NULL
.	NULL

Rev	NULL
.	NULL

Biochem	NULL
.	NULL

68	NULL
,	NULL
36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

23883	NULL
Hashimoto	NULL
,	NULL
Y.	NULL
,	NULL
Perrino	NULL
,	NULL
B	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Soderling	NULL
,	NULL
T.	NULL
R.	NULL
(	NULL
1990	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

265	NULL
,	NULL
1924-1927	NULL
Kissinger	NULL
,	NULL
C.	NULL
R.	NULL
,	NULL
Parge	NULL
,	NULL
H.	NULL
E.	NULL
,	NULL
Knighton	NULL
,	NULL
D.	NULL
R.	NULL
,	NULL
Lewis	NULL
,	NULL
C.	NULL
T.	NULL
,	NULL
Pelletier	NULL
,	NULL
L.	NULL
A.	NULL
,	NULL
Tempezyk	NULL
,	NULL
A.	NULL
,	NULL
Kalish	NULL
,	NULL
V.	NULL
J.	NULL
,	NULL
Tucker	NULL
,	NULL
K.	NULL
D.	NULL
,	NULL
Showalter	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
Moomaw	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
Gastinel	NULL
,	NULL
L.	NULL
N.	NULL
,	NULL
Habuka	NULL
,	NULL
N.	NULL
,	NULL
Chen	NULL
,	NULL
X.	NULL
,	NULL
Maldonado	NULL
,	NULL
F.	NULL
,	NULL
Barker	NULL
,	NULL
J.	NULL
E.	NULL
,	NULL
Bacquet	NULL
,	NULL
R.	NULL
,	NULL
and	NULL
Villafranca	NULL
,	NULL
J.	NULL
E.	NULL
(	NULL
1995	NULL
)	NULL
Nature	NULL
878	NULL
,	NULL
641-644	NULL
Griffith	NULL
,	NULL
J.	NULL
P.	NULL
,	NULL
Kim	NULL
,	NULL
J.	NULL
L.	NULL
,	NULL
Kim	NULL
,	NULL
E.	NULL
E.	NULL
,	NULL
Sintchak	NULL
,	NULL
M.	NULL
D.	NULL
,	NULL
Thomson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Fitzgibbon	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
Fleming	NULL
,	NULL
M.	NULL
A.	NULL
,	NULL
Caron	NULL
,	NULL
P.	NULL
R.	NULL
,	NULL
Hsiao	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Navia	NULL
,	NULL
M.	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
Cell	NULL
82	NULL
,	NULL
507-522	NULL
Schreiber	NULL
,	NULL
S.	NULL
L.	NULL
,	NULL
and	NULL
Crabtree	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1992	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
18	NULL
,	NULL
186-142	NULL
1045-1083	NULL
Liu	NULL
,	NULL
J	NULL
.	NULL

(	NULL
1993	NULL
)	NULL
Immunol	NULL
.	NULL

Today	NULL
14	NULL
,	NULL
290-295	NULL
Bierer	NULL
,	NULL
B.	NULL
E.	NULL
,	NULL
Hollander	NULL
,	NULL
G.	NULL
,	NULL
Fruman	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Burakoff	NULL
,	NULL
S.	NULL
J	NULL
.	NULL

(	NULL
1998	NULL
)	NULL
Curr	NULL
.	NULL

Opin	NULL
.	NULL

Immunol	NULL
.	NULL

5	NULL
,	NULL
168-773	NULL
Shirra	NULL
,	NULL
M.	NULL
K.	NULL
,	NULL
Zhu	NULL
,	NULL
Q.	NULL
,	NULL
Huang	NULL
,	NULL
H.-C.	NULL
,	NULL
Pallas	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Hansen	NULL
,	NULL
U	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

14	NULL
,	NULL
5076-5087	NULL
Mondragon	NULL
,	NULL
A.	NULL
,	NULL
Griffith	NULL
,	NULL
E.	NULL
C.	NULL
,	NULL
Sun	NULL
,	NULL
L.	NULL
,	NULL
Xiong	NULL
,	NULL
F.	NULL
,	NULL
Armstrong	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Liu	NULL
,	NULL
J.	NULL
O	NULL
.	NULL

(	NULL
1997	NULL
)	NULL
Biochemistry	NULL
36	NULL
,	NULL
4984-4942	NULL
Blumenthal	NULL
,	NULL
D.	NULL
K.	NULL
,	NULL
Takio	NULL
,	NULL
K.	NULL
,	NULL
Hansen	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
and	NULL
Krebs	NULL
,	NULL
E.	NULL
G.	NULL
(	NULL
1986	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

261	NULL
,	NULL
8140-8145	NULL
Nalefski	NULL
,	NULL
E.	NULL
A.	NULL
,	NULL
Shaw	NULL
,	NULL
K.	NULL
T.	NULL
Y.	NULL
,	NULL
and	NULL
Rao	NULL
,	NULL
A	NULL
.	NULL

(	NULL
1995	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

270	NULL
,	NULL
22351-22360	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL
T	NULL
wo-site	NULL
Interaction	NULL
of	NULL
Nuclear	NULL
Factor	NULL
of	NULL
Activated	NULL
T	NULL
Cells	NULL
with	NULL
Activated	NULL
Calcineurin	NULL
Francisco	NULL
J.	NULL
Garcia-Cozar	NULL
,	NULL
Heidi	NULL
Okamura	NULL
,	NULL
Jose	NULL
F.	NULL
Aramburu	NULL
,	NULL
Karen	NULL
T.	NULL
Y.	NULL
Shaw	NULL
,	NULL
Laura	NULL
Pelletier	NULL
,	NULL
Richard	NULL
Showalter	NULL
,	NULL
Ernest	NULL
Villafranca	NULL
and	NULL
Anjana	NULL
Rao	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1998	NULL
,	NULL
273:23877-23883.	NULL
doi	NULL
:	NULL
10.1074/jb0.273.37.23877	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/273/37/23877	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
41	NULL
references	NULL
,	NULL
19	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

